A review on interleukins: The key manipulators in rheumatoid arthritis

References

• Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. Eur J Radiol. 1998;27(1):S18–S24.
   PubMed Web of Science ®Google Scholar
• Malaviya AN, Kapoor SK, Singh RR, Kumar A, Pande I. Prevalence of rheumatoid arthritis in the adult Indian population. Rheumatol Int. 1993;13:131–4.
   PubMed Web of Science ®Google Scholar
• Gibofsky A. Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: a synopsis. Am J Manag Care. 2014;20:S128–S35.
   PubMed Web of Science ®Google Scholar
• Jones V, Taylor PCR, Jacoby RK, Wallington TB. Synovial synthesis of rheumatoid factors and immune complex constituents in early arthritis. Ann Rheum Dis. 1984;43:235–9.
   PubMed Web of Science ®Google Scholar
• Silverman GJ, Carson DA. Roles of B cells in rheumatoid arthritis. Arthritis Res Ther. 2003;5(4):S1–S6.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Berek C. B cells in rheumatoid arthritis. Arthritis Res. 2000;2:126–31.
   PubMedGoogle Scholar
• Willemze A, Toes REM, Huizinga TWJ, Trouw LA. New biomarkers in rheumatoid arthritis. Neth J Med. 2012;70:392–9.
   PubMed Web of Science ®Google Scholar
• Song YW, Kang EH. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM. 2010;103:139–46.
   PubMed Web of Science ®Google Scholar
• Wigerblad G, Bas DB, Fernades-Cerqueira C, Krishnamurthy A, Nandakumar KS, Rogoz K, et al. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. Ann Rheum Dis. 2016;75:730–8.
   PubMed Web of Science ®Google Scholar
• Wernick RM, Lipsky PE, Marban-Arcos E, Maliakkal JJ, Edelbaum D, and Ziff M. IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures. Arthritis Rheum. 1985;28:742–52.
   PubMed Web of Science ®Google Scholar
• Karouzakis E, Gay RE, Gay S, Neidhart M. Epigenetic control in rheumatoid arthritis synovial fibroblasts. Nat Rev Rheumatol. 2009;5:266–72.
   PubMed Web of Science ®Google Scholar
• Yoshihara Y, Nakamura H, Obata K, Yamada H, Hayakawa T, Fujikawa K, Okada Y. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis. 2000;59:455–61.
   PubMed Web of Science ®Google Scholar
• Yavropoulou MP, Yovos JG. Osteoclastogenesis–current knowledge and future perspectives. J Musculoskelet Neuronal Interact. 2008;8:204–16.
   PubMedGoogle Scholar
• Udagawa N, Kotake S, Kamatani N, Takahashi N, Suda T. The molecular mechanism of osteoclastogenesis in rheumatoid arthritis. Arthritis Res. 2002;4:281–9.
   PubMedGoogle Scholar
• Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero a, Timms E, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA. 1999;96:3540–5.
   PubMed Web of Science ®Google Scholar
• Kim N, Kadono Y, Takami M, Lee J, Lee SH, Okada F, et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med. 2005;202:589–95.
   PubMed Web of Science ®Google Scholar
• Otero JE, Dai S, Alhawagri MA, Darwech I, Abu-Amer Y. IKKbeta activation is sufficient for RANK-independent osteoclast differentiation and osteolysis. J Bone Miner Res. 2010;25:1282–94.
   PubMed Web of Science ®Google Scholar
• Mohr W, Hummler N, Pelster B, Wessinghage D. Proliferation of pannus tissue cells in rheumatoid arthritis. Rheumatol Int. 1986;6:127–32.
   PubMed Web of Science ®Google Scholar
• Kinne RW, Brauer R, Stuhlmüller B, Palomo-Kinnne E, Burmester GR. Review—macrophages in rheumatoid arthritis. Arthritis Res. 2000;2:189–202.
   PubMedGoogle Scholar
• Ishikawa H, Hirata S, Nishibayashin Y, Imura S, Kubo H, Ohno O. The role of adhesion molecules in synovial pannus formation in rheumatoid arthritis. Clin Orthop Relat Res. 1994;300:297–303.
   Google Scholar
• Ishikawa H, Hirata S, Andoh Y, Kubo H, Nakagawa N, Nishibayashi Y, Mizuno K. An immunohistochemical and immunoelectron microscopic study of adhesion molecules in synovial pannus formation in rheumatoid arthritis. Rheumatol Int. 1996;16:53–60.
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Besenyei T, Paragh G, Koch AE. Angiogenesis in rheumatoid arthritis. Autoimmunity. 2009;42:563–73.
   PubMed Web of Science ®Google Scholar
• Koch AE. The role of angiogenesis in rheumatoid arthritis: recent developments. Ann Rheum Dis. 2000;59:i65–71.
   PubMedGoogle Scholar
• Qi J, Ye X, Ren G, Kan F, Zhang Y, Guo M, et al. Pharmacological efficacy of anti-IL-1β scFv, Fab and full-length antibodies in treatment of rheumatoid arthritis. Mol Immunol. 2014;57:59–65.
   PubMed Web of Science ®Google Scholar
• Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol. 2015;15:283–94.
   PubMed Web of Science ®Google Scholar
• Wood NC, Symons JA, Duff GW. Serum interleukin-2-receptor in rheumatoid arthritis: a prognostic indicator of disease activity? J Autoimmun. 1988;1:353–61.
   PubMed Web of Science ®Google Scholar
• Hemmerle T, Doll F, Neri D. Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis. Proc Natl Acad Sci USA. 2014;111:12008–12.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014;73:1616–25.
   PubMed Web of Science ®Google Scholar
• Lee SK, Kalinowski JF, Jastrzebski SL, Puddington L, Lorenzo JA. Interleukin-7 is a direct inhibitor of in vitro osteoclastogenesis. Endocrinology. 2003;144:3524–31.
   PubMed Web of Science ®Google Scholar
• Weitzmann M, Cenci N, Rifas S, Brown L, Pacifici CR. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood. 2000;96:1873–8.
   PubMed Web of Science ®Google Scholar
• Troughton P. Synovial fluid interleukin-8 and neutrophil function in rheumatoid arthritis and seronegative polyarthritis. Rheumatology. 1996;35:1244–51.
   Web of Science ®Google Scholar
• Chernoff a. E, Granowitz EV, Shapiro L, Vannier E, Lonnemann G, Angel JB, et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol. 1995;154:5492–9.
   PubMed Web of Science ®Google Scholar
• Trepicchio WL, Bozza M, Pedneault G, Dorner a. J. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol. 1996;157:3627–34.
   PubMed Web of Science ®Google Scholar
• Girasole G, Passeri G, Jilka RL, Manolagas SC. Interleukin-11: a new cytokine critical for osteoclast development. J Clin Invest. 1994;93:1516–24.
   PubMed Web of Science ®Google Scholar
• Butler DM, Malfait AM, Maini RN, Brennan FM, Feldmann M. Anti-IL-12 and anti-TNF antibodies synergistically suppress the progression of murine collagen-induced arthritis. Eur J Immunol. 1999;29:2205–12.
   PubMed Web of Science ®Google Scholar
• Woods JM, Katschke KJ, Tokuhira M, Kurata H, Arai KI, Campbell PL, Koch AE. Reduction of inflammatory cytokines and prostaglandin E2 by IL-13 gene therapy in rheumatoid arthritis synovium. J Immunol. 2000;165:2755–63.
   PubMed Web of Science ®Google Scholar
• Fujisawa T, Joshi BH, Puri RK. IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer. Int J Cancer. 2012;131:344–56.
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases. Arthritis Res Ther. 2004;6:174–7.
   PubMed Web of Science ®Google Scholar
• Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, et al. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol. 2014;41:414–21.
   PubMed Web of Science ®Google Scholar
• Zhu S, Pan W, Song X, Liu Y, Shao X, Tang Y, et al. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α. Nat Med. 2012;18:1077–86.
   PubMed Web of Science ®Google Scholar
• Plater-Zyberk C, Joosten L, Helsen M, Sattonnet-Roche P, Siegfried C, Alouani S, et al. IL-18 blockade is a potential disease-modifying therapy for rheumatoid arthritis. Arthritis Res. 2001;3:P092.
   Google Scholar
• Hsu YH, Hsieh PP, Chang MS. Interleukin-19 blockade attenuates collagen-induced arthritis in rats. Rheumatology (Oxford). 2012;51:434–42.
   PubMed Web of Science ®Google Scholar
• Šenolt L, Leszczynski P, Dokoupilová E, Göthberg M, Valencia X, Hansen BB, Cañete JD. Efficacy and safety of anti-interleukin-20 monoclonal antibody in patients with rheumatoid arthritis: a randomized phase IIa trial. Arthritis Rheumatol. 2015;67:1438–48.
   PubMed Web of Science ®Google Scholar
• Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, Lowe L, et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum. 2007;56:1152–63.
   PubMed Web of Science ®Google Scholar
• Kim KW, Kim HR, Park JY, Park JS, Oh HJ, Woo YJ, et al. Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum. 2012;64:1015–23.
   PubMed Web of Science ®Google Scholar
• Geboes L, Dumoutier L, Kelchtermans H, Schurgers E, Mitera T, Renauld JC, Matthys P. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum. 2009;60:390–5.
   PubMed Web of Science ®Google Scholar
• Chen Y, Langrish CL, Mckenzie B, Joyce-Shaikh B, Stumhofer JS, McClanahan T, et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J Clin Invest. 2006;116:1317–26.
   PubMed Web of Science ®Google Scholar
• Nishikawa T, Ramesh R, Munshi A, Chada S, Meyn RE. Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation. Mol Ther. 2004;9:818–28.
   PubMed Web of Science ®Google Scholar
• Amirzada MI, Jin J. Therapeutic applications of interleukin 24 (IL24): a review. Trop J Pharm Res. 2012;11:1023–7.
   Web of Science ®Google Scholar
• Gong F, Pan YH, Huang X, Chen J, Xiao JH, Zhu HY. Interleukin-27 as a potential therapeutic target for rheumatoid arthritis: has the time come? Clin Rheumatol. 2013;32:1425–8.
   PubMed Web of Science ®Google Scholar
• Wang F, Xu L, Feng X, Guo D, Tan W, Zhang M. Interleukin-29 modulates proinflammatory cytokine production in synovial inflammation of rheumatoid arthritis. Arthritis Res Ther. 2012;14:R228.
   PubMed Web of Science ®Google Scholar
• Kageyama Y, Torikai E, Tsujimura K, Kobayashi M. Involvement of IL-33 in the pathogenesis of rheumatoid arthritis: the effect of etanercept on the serum levels of IL-33. Mod Rheumatol. 2012;22:89–93.
   PubMed Web of Science ®Google Scholar
• Zhang F, Ding R, Li P, Ma C, Song D, Wang X, et al. Interleukin-34 in rheumatoid arthritis: potential role in clinical therapy. Int J Clin Exp Med. 2015;8:7809–15.
   PubMed Web of Science ®Google Scholar
• Thiolat A, Denys A, Petit M, Biton J, Lemeiter D, Herve R, et al. Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice. Cytokine. 2014;69:87–93.
   PubMed Web of Science ®Google Scholar
• Ye L, Jiang B, Deng J, Du J, Xiong W, Guan Y, et al. IL-37 alleviates rheumatoid arthritis by suppressing IL-17 and IL-17-triggering cytokine production and limiting Th17 cell proliferation. J Immunol. 2015;194:5110–19.
   PubMed Web of Science ®Google Scholar
• Dinarello CH. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095–147.
   PubMed Web of Science ®Google Scholar
• Vigers GP, Anderson LJ, Caffes P, Brandhuber BJ. Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta. Nature. 1997;386:190–4.
   PubMed Web of Science ®Google Scholar
• Lopalco G, Cantarini L, Vitale A, Iannone F, Anelli MG, Andreozzi L, et al. Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediators Inflamm. 2015;2015:194864.
   Web of Science ®Google Scholar
• Bingham CO. The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J Rheumatol. 2002;29:3–9.
   PubMed Web of Science ®Google Scholar
• Henderson B, Pettipher ER. Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol. 1989;75:306–10.
   PubMed Web of Science ®Google Scholar
• Luft T, Jefford M, Luetjens P, Hochrein H, Masterman KA, Maliszewski C, et al. IL-1 enhances CD40 ligand-mediated cytokine secretion by human dendritic cells (DC): a mechanism for T cell-independent DC activation. J Immunol. 2002;168:713–22.
   PubMed Web of Science ®Google Scholar
• Wesa AK, Galy A. IL-1 beta induces dendritic cells to produce IL-12. Int Immunol. 2001;13:1053–61.
   PubMed Web of Science ®Google Scholar
• Tsakiri N, Kimber I, Rothwell NJ, Pinteaux E. Interleukin-1-induced interleukin-6 synthesis is mediated by the neutral sphingomyelinase/Src kinase pathway in neurones. Br J Pharmacol. 2008;153:775–83.
   PubMed Web of Science ®Google Scholar
• Kasahara T, Mukaida N, Yamashita K, Yagisawa H, Akahoshi T, Matsushima K. IL-1 and TNF-alpha induction of IL-8 and monocyte chemotactic and activating factor (MCAF) mRNA expression in a human astrocytoma cell line. Immunology. 1991;74:60–7.
   PubMed Web of Science ®Google Scholar
• Patil C, Zhu X, Rossa C, Kim YJ, Kirkwood KL. p38 MAPK regulates IL-1beta induced IL-6 expression through mRNA stability in osteoblasts. Immunol Invest. 2004;33:213–33.
   PubMed Web of Science ®Google Scholar
• Voronov E, Carmi Y, Apte RN. The role IL-1 in tumor-mediated angiogenesis. Front Physiol. 2014; 5:1–11.
   PubMed Web of Science ®Google Scholar
• Haraldsen G, Kvale D, Lien B, Farstad IN, Brandtzaeg P. Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human microvascular endothelial cells. J Immunol. 1996;156:2558–65.
   PubMed Web of Science ®Google Scholar
• Salven P. Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. FASEB J. 2002;16:1471–3.
   PubMed Web of Science ®Google Scholar
• Carmi Y, Dotan S, Rider P, Kaplanov I, White MR, Baron R, et al. The role of IL-1β in the early tumor cell-induced angiogenic response. J Immunol. 2013;190:3500–9.
   PubMed Web of Science ®Google Scholar
• Lee EG, Sung MS, Yoo HG, Chae HJ, Kim HR, Yoo WH. Increased RANKL-mediated osteoclastogenesis by interleukin-1β and endoplasmic reticulum stress. Joint Bone Spine. 2014;81:520–6.
   PubMed Web of Science ®Google Scholar
• Lee WS, Lee EG, Sung MS, Yoo WH. Kaempferol inhibits IL-1β-stimulated, RANKL-mediated osteoclastogenesis via downregulation of MAPKs, c-Fos, and NFATc1. Inflammation. 2014;37:1221–30.
   PubMed Web of Science ®Google Scholar
• Arend WP. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin Arthritis Rheum. 2001;30:1–6.
   PubMed Web of Science ®Google Scholar
• Mertens M, Singh J. Anakinra for rheumatoid arthritis. Cochrane Database Syst Rev. 2009;36:CD005121.
   Google Scholar
• Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009;22:240–73.
   PubMed Web of Science ®Google Scholar
• Sugamura K. [Structure and function of IL-2 receptor subunits]. Hum Cell. 1994;7:1–5.
   PubMedGoogle Scholar
• Karasuyama H, Tohyama N, Tada T. Autocrine growth and tumorigenicity of interleukin 2-dependent helper T cells transfected with IL-2 gene. J Exp Med. 1989;169:13–25.
   PubMed Web of Science ®Google Scholar
• Waldner C, Mongini C, Alvarez E, Sánchez Lockhart M, Gravisaco M, Hajos S. Interleukin 2 exerts autocrine stimulation on murine T-cell leukaemia growth. Br J Cancer. 1997;75:946–50.
   PubMed Web of Science ®Google Scholar
• Kim MH, Kitson RP, Albertsson P, Nannmark U, Basse PH, Kuppen PJK, et al. Secreted and membrane-associated matrix metalloproteinases of IL-2-activated NK cells and their inhibitors. J Immunol. 2000;164:5883–9.
   PubMed Web of Science ®Google Scholar
• Kitas GD, Salmon M, Farr M, Gaston JS, Bacon PA. Deficient interleukin 2 production in rheumatoid arthritis: association with active disease and systemic complications. Clin Exp Immunol. 1988;73:242–9.
   PubMed Web of Science ®Google Scholar
• Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013;38:13–25.
   PubMed Web of Science ®Google Scholar
• Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol. 2011;23:598–604.
   PubMed Web of Science ®Google Scholar
• Ballesteros-Tato A, León B, Graf BA, Moquin A, Adams PS, Lund FE, Randall TD. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity. 2012;36:847–56.
   PubMed Web of Science ®Google Scholar
• Davidson TS, DiPaolo RJ, Andersson J, Shevach EM. Cutting edge: IL-2 is essential for TGF-beta-mediated induction of Foxp3+ T regulatory cells. J Immunol. 2007;178:4022–6.
   PubMed Web of Science ®Google Scholar
• Sharma R, Fu SM, Ju ST. IL-2: a two-faced master regulator of autoimmunity. J Autoimmun. 2011;36:91–7.
   PubMed Web of Science ®Google Scholar
• Bouchentouf M, Williams P, Forner KA, Cuerquis J, Michaud V, Paradis P, et al. Interleukin-2 enhances angiogenesis and preserves cardiac function following myocardial infarction. Cytokine. 2011;56:732–8.
   PubMed Web of Science ®Google Scholar
• Pascual J, Marcén R, Ortuño J. Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab. Nephrol Dial Transplant. 2001;16:1756–60.
   PubMed Web of Science ®Google Scholar
• A Randomized, Double Blind, Placebo-controlled Pilot-study to Evaluate Efficacy and Safety of Low-dose hrIL-2 in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-Naive Patients with Rheumatoid Arthritis (n.d.). Available from: https://clinicaltrials.gov/ct2/show/NCT02467504 (accessed 28 April 2016).
   Google Scholar
• Broughton SE, Dhagat U, Hercus TR, Nero TL, Grimbaldeston MA, Bonder CS, et al. The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol Rev. 2012;250:277–302.
   PubMed Web of Science ®Google Scholar
• Hara T, Miyajima A. Function and signal transduction mediated by the interleukin 3 receptor system in hematopoiesis. Stem Cells. 1996;14:605–18.
   PubMed Web of Science ®Google Scholar
• Brown MP, Nosaka T, Tripp RA, Brooks J, van Deursen JM, Brenner MK, et al. Reconstitution of early lymphoid proliferation and immune function in Jak3-deficient mice by interleukin-3. Blood. 1999;94:1906–14.
   PubMed Web of Science ®Google Scholar
• Yogesha SD, Khapli SM, Srivastava RK, Mangashetti LS, Pote ST, Mishra GC, Wani MR. IL-3 inhibits TNF-alpha-induced bone resorption and prevents inflammatory arthritis. J Immunol. 2009;182:361–70.
   PubMed Web of Science ®Google Scholar
• Gillespie MT. Impact of cytokines and T lymphocytes upon osteoclast differentiation and function. Arthritis Res Ther. 2007;9:103.
   PubMed Web of Science ®Google Scholar
• Srivastava RK, Tomar GB, Barhanpurkar AP, Gupta N, Pote ST, Mishra GC, Wani MR. IL-3 attenuates collagen-induced arthritis by modulating the development of Foxp3+ regulatory T cells. J Immunol. 2011;186:2262–72.
   PubMed Web of Science ®Google Scholar
• Wang T, Secombes CJ. The evolution of IL-4 and IL-13 and their receptor subunits. Cytokine. 2015;75:8–13.
   PubMed Web of Science ®Google Scholar
• Noben-Trauth N, Hu-Li J, Paul WE. IL-4 secreted from individual naive CD4+ T cells acts in an autocrine manner to induce Th2 differentiation. Eur J Immunol. 2002;32:1428–33.
   PubMed Web of Science ®Google Scholar
• Stewart D, Javadi M, Chambers M, Gunsolly C, Gorski G, Borghaei RC. Interleukin-4 inhibition of interleukin-1-induced expression of matrix metalloproteinase-3 (MMP-3) is independent of lipoxygenase and PPARgamma activation in human gingival fibroblasts. BMC Mol Biol. 2007;8:12.
   PubMed Web of Science ®Google Scholar
• Fenton MJ, Buras JA, Donnelly RP. IL-4 reciprocally regulates IL-1 and IL-1 receptor antagonist expression in human monocytes. J Immunol. 1992;149:1283–8.
   PubMed Web of Science ®Google Scholar
• Pakdel MBF, Farhadi F, Pouralibaba F, Kahnamouii SS, Farshi MR, Shirani G. IL-4 regulate the pro-inflammatory cytokines in rheumatoid arthritis. Adv Environ Biol. 2014;8:383–7.
   Google Scholar
• Bhattacharjee A, Shukla M, Yakubenko VP, Mulya A, Kundu S, Cathcart MK. IL-4 and IL-13 employ discrete signaling pathways for target gene expression in alternatively activated monocytes/macrophages. Free Radic Biol Med. 2013;54:1–16.
   PubMed Web of Science ®Google Scholar
• Taki H. Interleukin-4 inhibits interleukin-11 production by rheumatoid synovial cells. Rheumatology (Oxford). 2000;39:728–31.
   PubMed Web of Science ®Google Scholar
• Abu-Amer Y. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. J Clin Invest. 2001;107:1375–85.
   PubMed Web of Science ®Google Scholar
• Bendixen AC, Shevde NK, Dienger KM, Willson TM, Funk CD, Pike JW. IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci USA. 2001;98:2443–8.
   PubMed Web of Science ®Google Scholar
• Moon B, Takaki S, Miyake K, Takatsu K. The role of IL-5 for mature B-1 cells in homeostatic proliferation, cell survival, and Ig production. J Immunol. 2004;172:6020–9.
   PubMed Web of Science ®Google Scholar
• Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol. 2009;21:1303–9.
   PubMed Web of Science ®Google Scholar
• Ikutani M, Yanagibashi T, Ogasawara M, Tsuneyama K, Yamamoto S, Hattori Y, et al. Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J Immunol. 2012;188:703–13.
   PubMed Web of Science ®Google Scholar
• Tran GT, Hodgkinson SJ, Carter NM, Verma ND, Plain KM, Boyd R, et al. IL-5 promotes induction of antigen-specific CD4 + CD25+ T regulatory cells that suppress autoimmunity. Blood. 2012;119:4441–50.
   PubMed Web of Science ®Google Scholar
• Pedersen BK, Fischer CP. Beneficial health effects of exercise-the role of IL-6 as a myokine. Trends Pharmacol Sci. 2007;28:152–6.
   PubMed Web of Science ®Google Scholar
• Wada TT, Araki Y, Sato K, Aizaki Y, Yokota K, Kim YT, et al. Aberrant histone acetylation contributes to elevated interleukin-6 production in rheumatoid arthritis synovial fibroblasts. Biochem Biophys Res Commun. 2014;444:682–6.
   PubMed Web of Science ®Google Scholar
• Georganas C, Liu H, Perlman H, Hoffmann A, Thimmapaya B, Pope RM. Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-kappa B but not C/EBP beta or c-Jun. J Immunol. 2000;165:7199–206.
   PubMed Web of Science ®Google Scholar
• Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, et al. Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol. 1988;18:1797–801.
   PubMed Web of Science ®Google Scholar
• Hashizume M, Hayakawa N, Suzuki M, Mihara M. IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system. Rheumatol Int. 2009;29:1449–54.
   PubMed Web of Science ®Google Scholar
• Gopinathan G, Milagre C, Pearce OMT, Reynolds LE, Hodivala-Dilke K, Leinster DA, et al. Interleukin-6 stimulates defective angiogenesis. Cancer Res. 2015;75:3098–107.
   PubMed Web of Science ®Google Scholar
• Palmqvist P, Persson E, Conaway HH, Lerner UH. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF- B ligand, osteoprotegerin, and receptor activator of NF- B in mouse calvariae. J Immunol. 2002;169:3353–62.
   PubMed Web of Science ®Google Scholar
• Yoshitake F, Itoh S, Narita H, Ishihara K, Ebisu S. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-kappaB signaling pathways. J Biol Chem. 2008;283:11535–40.
   PubMed Web of Science ®Google Scholar
• Korn T, Mitsdoerffer M, Croxford AL, Awasthi A, Dardalhon VA, Galileos G, et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci USA. 2008;105:18460–5.
   PubMed Web of Science ®Google Scholar
• Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance. Eur J Immunol. 2010;40:1830–5.
   PubMed Web of Science ®Google Scholar
• Helal AMH, Shahine EM, Hassan MM, Hashad DI, Moneim RA. Fatigue in rheumatoid arthritis and its relation to interleukin-6 serum level. Egypt Rheumatol. 2012;34:153–7.
   Google Scholar
• Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database Syst Rev. 2010;7:CD008331.
   Google Scholar
• Van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman’s disease. J Clin Oncol. 2010;28:3701–8.
   PubMed Web of Science ®Google Scholar
• Gonzales AM, Orlando RA. Curcumin and resveratrol inhibit nuclear factor-kappaB-mediated cytokine expression in adipocytes. Nutr Metab (Lond). 2008;5:17.
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Kasai H, Watanabe A, Lai AY, Kondo M. IL-7 specifies B cell fate at the common lymphoid progenitor to pre-proB transition stage by maintaining early B cell factor expression. J Immunol. 2008;181:383–92.
   PubMed Web of Science ®Google Scholar
• Akashi K, Kondo M, Weissman IL. Role of interleukin-7 in T-cell development from hematopoietic stem cells. Immunol Rev. 1998;165:13–28.
   PubMed Web of Science ®Google Scholar
• Kang J, Coles M. IL-7: the global builder of the innate lymphoid network and beyond, one niche at a time. Semin Immunol. 2012;24:190–7.
   PubMed Web of Science ®Google Scholar
• Churchman SM, El-Jawhari JJ, Burska AN, Parmar R, Goëb V, Conaghan PG, et al. Modulation of peripheral T-cell function by interleukin-7 in rheumatoid arthritis. Arthritis Res Ther. 2014;16:511.
   PubMed Web of Science ®Google Scholar
• Chen Z, Kim S, Chamberlain ND, Pickens SR, Volin MV, Volkov S, et al. The novel role of IL-7 ligation to IL-7 receptor in myeloid cells of rheumatoid arthritis and collagen-induced arthritis. J Immunol. 2013;190:5256–66.
   PubMed Web of Science ®Google Scholar
• Ponchel F, Verburg RJ, Bingham SJ, Brown AK, Moore J, Protheroe A, et al. Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. Rthritis Res Ther. 2005;7:R80–92.
   PubMed Web of Science ®Google Scholar
• van Roon JA, Verweij MC, Wijk MW, Jacobs KM, Bijlsma JW. Increased intraarticular interleukin-7 in rheumatoid arthritis patients stimulates cell contact-dependent activation of CD4(+) T cells and macrophages. Arthritis Rheum. 2005;52:1700–10.
   PubMed Web of Science ®Google Scholar
• Murphy PM. Neutrophil receptors for interleukin-8 and related CXC chemokines. Semin Hematol. 1997;34:311–18.
   PubMed Web of Science ®Google Scholar
• Hwang SY, Kim JY, Kim KW, Park MK, Moon Y, Kim WU, Kim HY. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther. 2004;6:R120–8.
   PubMed Web of Science ®Google Scholar
• Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, Knight JS, et al. NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med. 2013;5:178ra40.
   PubMed Web of Science ®Google Scholar
• Manna SK, Ramesh GT. Interleukin-8 induces nuclear transcription factor-kappaB through a TRAF6-dependent pathway. J Biol Chem. 2005;280:7010–21.
   PubMed Web of Science ®Google Scholar
• Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease. Bone. 2003;33:28–37.
   PubMed Web of Science ®Google Scholar
• Li A, Dubey S, Varney ML, Bhavana J, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol. 2003;170:3369–76.
   PubMed Web of Science ®Google Scholar
• Peichl P, Pursch E, Bröll H, Lindley IJD. Anti-IL-8 autoantibodies and complexes in rheumatoid arthritis: polyclonal activation in chronic synovial tissue inflammation. Rheumatol Int. 1999;18:141–5.
   PubMed Web of Science ®Google Scholar
• Fang Y, Chen X, Bai Q, Qin C, Mohamud AO, Zhu Z, et al. IL-9 inhibits HTB-72 melanoma cell growth through upregulation of p21 and TRAIL. J Surg Oncol. 2015;111:969–74.
   PubMed Web of Science ®Google Scholar
• Demoulin J, Van Snick BJ, Renauld JC. Interleukin-9 (IL-9) induces cell growth arrest associated with sustained signal transducer and activator of transcription activation in lymphoma cells overexpressing the IL-9 receptor. Cell Growth Differ. 2001;12:169–74.
   PubMedGoogle Scholar
• Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol. 2008;9:1347–55.
   PubMed Web of Science ®Google Scholar
• Wong MT, Ye JJ, Alonso MN, Landrigan A, Cheung RK, Engleman E, Utz PJ. Regulation of human Th9 differentiation by type I interferons and IL-21. Immunol Cell Biol. 2010;88:624–31.
   PubMed Web of Science ®Google Scholar
• Ma CS, Tangye SG, Deenick EK. Human Th9 cells: inflammatory cytokines modulate IL-9 production through the induction of IL-21. Immunol Cell Biol. 2010;88:621–3.
   PubMed Web of Science ®Google Scholar
• Elyaman W, Bradshaw EM, Uyttenhove C, Dardalhon V, Awasthi A, Imitola J, et al. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci USA. 2009;106:12885–90.
   PubMed Web of Science ®Google Scholar
• Ciccia F, Guggino G, Rizzo A, Manzo A, Vitolo B, Pio M, et al. Potential involvement of IL-9 and Th9 cells in the pathogenesis of rheumatoid arthritis. Rheumatology. 2015;54:1–9.
   Web of Science ®Google Scholar
• Dantas AT, Marques CDL, da Rocha Junior LF, Cavalcanti MB, Gonçalves SMC, Cardoso PRG, et al. Increased serum interleukin-9 levels in rheumatoid arthritis and systemic lupus erythematosus: pathogenic role or just an epiphenomenon? Dis Markers. 2015;2015:519638.
   PubMed Web of Science ®Google Scholar
• Singh TP, Schön MP, Wallbrecht K, Gruber-Wackernagel A, Wang XJ, Wolf P. Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis. PLoS One. 2013;8:1–11.
   Web of Science ®Google Scholar
• Sismanopoulos N, Delivanis DA, Alysandratos KD, Angelidou A, Vasiadi M, Therianou A, Theoharides TC. IL-9 induces VEGF secretion from human mast cells and IL-9/IL-9 receptor genes are overexpressed in atopic dermatitis. PLoS One. 2012;7:5–9.
   Web of Science ®Google Scholar
• O’Garra A, Moore KW, de Waal Malefyt R, Coffman RL. Interleukin-10 and the interleukin-10 Receptor. Annu Rev Immunol. 2001;19:683–765.
   PubMed Web of Science ®Google Scholar
• McGuirk P, McCann C, Mills KH. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med. 2002;195:221–31.
   PubMed Web of Science ®Google Scholar
• O’Garra A, Vieira P. T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol. 2007;7:425–8.
   PubMed Web of Science ®Google Scholar
• Yilma AN, Singh SR, Fairley SJ, Taha MA, Dennis VA. The anti-inflammatory cytokine, interleukin-10, inhibits inflammatory mediators in human epithelial cells and mouse macrophages exposed to live and UV-inactivated chlamydia trachomatis. Mediators Inflamm. 2012;2012:520174.
   PubMed Web of Science ®Google Scholar
• de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174:1209–20.
   PubMed Web of Science ®Google Scholar
• Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med. 1993;178:2207–11.
   PubMed Web of Science ®Google Scholar
• Zhou L, Nazarian AA, Smale ST. Interleukin-10 inhibits interleukin-12 p40 gene transcription by targeting a late event in the activation pathway. Mol Cell Biol. 2004;24:2385–96.
   PubMed Web of Science ®Google Scholar
• Driessler F, Venstrom K, Sabat R, Asadullah K, Schottelius AJ. Molecular mechanisms of interleukin-10-mediated inhibition of NF-kappaB activity: a role for p50. Clin Exp Immunol. 2004;135:64–73.
   PubMed Web of Science ®Google Scholar
• Yao Y, Li W, Kaplan MH, Chang CH. Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells. J Exp Med. 2005;201:1899–903.
   PubMed Web of Science ®Google Scholar
• Groux H, Cottrez F. The complex role of interleukin-10 in autoimmunity. J Autoimmun. 2003;20:281–5.
   PubMed Web of Science ®Google Scholar
• Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol. 1998;160:3555–61.
   PubMed Web of Science ®Google Scholar
• Satoguina JS, Weyand E, Larbi J, Hoerauf A. T regulatory-1 cells induce IgG4 production by B cells: role of IL-10. J Immunol. 2005;174:4718–26.
   PubMed Web of Science ®Google Scholar
• Heo YJ, Joo YB, Oh HJ, Park MK, Heo YM, Cho ML, et al. IL-10 suppresses Th17 cells and promotes regulatory T cells in the CD4+ T cell population of rheumatoid arthritis patients. Immunol Lett. 2010;127:150–6.
   PubMed Web of Science ®Google Scholar
• Huber S, Gagliani N, Esplugues E, O’Connor W, Huber FJ, Chaudhry A, et al. Th17 cells express interleukin-10 receptor and are controlled by Foxp3? and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity. 2011;34:554–65.
   PubMed Web of Science ®Google Scholar
• Alexandrakis MG, Goulidaki N, Pappa CA, Boula A, Psarakis F, Neonakis I, Tsirakis G. Interleukin-10 induces both plasma cell proliferation and angiogenesis in multiple myeloma. Pathol Oncol Res. 2015;21:929–34.
   PubMed Web of Science ®Google Scholar
• Dace DS, Khan AA, Kelly J, Apte RS. Interleukin-10 promotes pathological angiogenesis by regulating macrophage response to hypoxia during development. PLoS One. 2008;3:e3381.
   PubMed Web of Science ®Google Scholar
• Wu WK, Llewellyn OPC, Bates DO, Nicholson LB, Dick AD. IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia. Immunobiology. 2010;215:796–803.
   PubMed Web of Science ®Google Scholar
• KohnoMizukami T, Suzuki H, Saga M, Takei Y, Shimpo Y, Matsushita M, et al. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res. 2003;63:5091–4.
   PubMed Web of Science ®Google Scholar
• Takayanagi H. The role of NFAT in osteoclast formation. Ann N Y Acad Sci. 2007;1116:227–37.
   PubMed Web of Science ®Google Scholar
• Evans KE, Fox SW. Interleukin-10 inhibits osteoclastogenesis by reducing NFATc1 expression and preventing its translocation to the nucleus. BMC Cell Biol. 2007;8:4.
   PubMed Web of Science ®Google Scholar
• Cush JJ, Splawski JB, Thomas R, McFarlin JE, Schulze-Koops H, Davis LS, et al. Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:96–104.
   PubMed Web of Science ®Google Scholar
• Van Roon JAG, Wijngaarden S, Lafeber FPJG, Damen C, Van JG, Winkel JD, Bijlsma JWJ. Interleukin 10 treatment of patients with rheumatoid arthritis enhances Fcγ receptor expression on monocytes and responsiveness to immune complex stimulation. J Rheumatol. 2003;30:648–51.
   PubMed Web of Science ®Google Scholar
• Keystone E, Wherry J, Grint P. IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am. 1998;24:629–39.
   PubMed Web of Science ®Google Scholar
• Trepicchio WL, Dorner AJ. Interleukin-11. A gp130 cytokine. Ann N Y Acad Sci. 1998;856:12–21.
   PubMed Web of Science ®Google Scholar
• Nandurkar HH, Robb L, Tarlinton D, Barnett L, Köntgen F, Begley CG. Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis. Blood. 1997;90:2148–59.
   PubMed Web of Science ®Google Scholar
• DA W, Keller DC, Du XX, Srour EF, Hoffman R. Interleukin-11 inhibits adipogenesis and stimulates myelopoiesis in human long-term marrow cultures. Blood. 1993;82:1428–35.
   PubMed Web of Science ®Google Scholar
• Nandurkar HH, Robb L, Begley CG. The role of IL-II in hematopoiesis as revealed by a targeted mutation of its receptor. Stem Cells. 1998;16(2):53–65.
   PubMedGoogle Scholar
• Sims NA, Jenkins BJ, Nakamura A, Quinn JMW, Li R, Gillespie MT, et al. Interleukin-11 receptor signaling is required for normal bone remodeling. J Bone Miner Res. 2005;20:1093–102.
   PubMed Web of Science ®Google Scholar
• Teramura M, Kobayashi S, Yoshinaga K, Iwabe K, Mizoguchi H. Effect of interleukin 11 on normal and pathological thrombopoiesis. Cancer Chemother Pharmacol. 1996;38:S99–S102.
   PubMed Web of Science ®Google Scholar
• Li TM, Wu CM, Huang HC, Chou PC, Fong YC, Tang CH. Interleukin-11 increases cell motility and up-regulates intercellular adhesion molecule-1 expression in human chondrosarcoma cells. J Cell Biochem. 2012;113:3353–62.
   PubMed Web of Science ®Google Scholar
• Onnis B, Fer N, Rapisarda A, Perez VS, Melillo G. Autocrine production of IL-11 mediates tumorigenicity in hypoxic cancer cells. J Clin Invest. 2013;123:1615–29.
   PubMed Web of Science ®Google Scholar
• Matsui T, Nakata N, Nagai S, Nakatani A, Takahashi M, Momose T, et al. Inflammatory cytokines and hypoxia contribute to 18F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis. J Nucl Med. 2009;50:920–6.
   PubMed Web of Science ®Google Scholar
• Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone. 2003;32:1–7.
   PubMed Web of Science ®Google Scholar
• Morgan H, Tumber A, Hill PA. Breast cancer cells induce osteoclast formation by stimulating host IL-11 production and downregulating granulocyte/macrophage colony-stimulating factor. Int J Cancer. 2004;109:653–60.
   PubMed Web of Science ®Google Scholar
• McCoy EM, Hong H, Pruitt HC, Feng X. IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells. BMC Cancer. 2013;13:16.
   PubMed Web of Science ®Google Scholar
• Hermann JA, Hall MA, Maini RN, Feldmann M, Brennan FM. Important immunoregulatory role of interleukin-11 in the inflammatory process in rheumatoid arthritis. Arthritis Rheum. 1998;41:1388–97.
   PubMed Web of Science ®Google Scholar
• Presky DH, Yang H, Minetti LJ, Chua AO, Nabavi N, Wu CY, et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA. 1996;93:14002–7.
   PubMed Web of Science ®Google Scholar
• Ylikoski E, Lund R, Kyläniemi M, Filén S, Kilpeläinen M, Savolainen J, Lahesmaa R. IL-12 up-regulates T-bet independently of IFN-gamma in human CD4+ T cells. Eur J Immunol. 2005;35:3297–306.
   PubMed Web of Science ®Google Scholar
• Koch A, Raidl M, Lux M, Müller K, Büning H, Humme S. IL-12-induced T-bet expression and IFNgamma release in lymphocytes from asthmatics–role of MAPkinases ERK-1/-2, p38(MAPK) and effect of dexamethasone. Respir Med. 2007;101:1321–30.
   PubMed Web of Science ®Google Scholar
• Knutson KL, Disis ML. IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion. Clin Exp Immunol. 2004;135:322–9.
   PubMed Web of Science ®Google Scholar
• Windhagen A, Anderson DE, Carrizosa A, Williams RE, Hafler DA. IL-12 induces human T cells secreting IL-10 with IFN-gamma. J Immunol. 1996;157:1127–31.
   PubMed Web of Science ®Google Scholar
• Wu CY, Demeure C, Kiniwa M, Gately M, Delespesse G. IL-12 induces the production of IFN-gamma by neonatal human CD4 T cells. J Immunol (Baltimore, Md 1950). 1993;151:1938–49.
   PubMed Web of Science ®Google Scholar
• Yoshimatsu M, Kitaura H, Fujimura Y, Eguchi T, Kohara H, Morita Y, Yoshida N. IL-12 inhibits TNF-α induced osteoclastogenesis via a T cell-independent mechanism in vivo. Bone. 2009;45:1010–16.
   PubMed Web of Science ®Google Scholar
• Yoshimatsu M, Kitaura H, Fujimura Y, Kohara H, Morita Y, Yoshida N. IL-12 inhibits lipopolysaccharide stimulated osteoclastogenesis in mice. J Immunol Res. 2014;2015:214878.
   Google Scholar
• Albini A, Brigati C, Ventura A, Lorusso G, Pinter M, Morini M, et al. Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target. J Transl Med. 2009;7:5.
   PubMed Web of Science ®Google Scholar
• Morini M, Albini A, Lorusso G, Moelling K, Lu B, Cilli M, et al. Prevention of angiogenesis by naked DNA IL-12 gene transfer: angioprevention by immunogene therapy. Gene Ther. 2004;11:284–91.
   PubMed Web of Science ®Google Scholar
• Horwood NJ, Elliott J, Martin TJ, Gillespie MT. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol. 2001;166:4915–21.
   PubMed Web of Science ®Google Scholar
• Lexberg MH, Taubner A, Albrecht I, Lepenies I, Richter A, Kamradt T, et al. IFN-γ and IL-12 synergize to convert in vivo generated Th17 into Th1/Th17 cells. Eur J Immunol. 2010;40:3017–27.
   PubMed Web of Science ®Google Scholar
• Peeva E, Fishman AD, Goddard G, Wadler S, Barland P. Rheumatoid arthritis exacerbation caused by exogenous interleukin-12. Arthritis Rheum. 2000;43:461.
   PubMed Web of Science ®Google Scholar
• Kim WU, Min SY, Cho ML, Youn J, Min JK, Lee SH, et al. The role of IL-12 in inflammatory activity of patients with rheumatoid arthritis (RA). Clin Exp Immunol. 2000;119:175–81.
   PubMed Web of Science ®Google Scholar
• Morita Y, Yamamura M, Nishida K, Harada S, Okamoto H, Inoue H, et al. Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis Rheum. 1998;41:306–14.
   PubMed Web of Science ®Google Scholar
• Aita T, Yamamura M, Kawashima M, Okamoto A, Iwahashi M, Yamana J, Makino H. Expression of interleukin 12 receptor (IL-12R) and IL-18R on CD4+ T cells from patients with rheumatoid arthritis. J Rheumatol. 2004;31:448–56.
   PubMed Web of Science ®Google Scholar
• Derocq JM, Dumont X, Guillemot JC, Kaghad M, Labit C, Leplatois P, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature. 1993;362:248–50.
   PubMed Web of Science ®Google Scholar
• Khurana Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol. 2003;111:677–90.
   PubMed Web of Science ®Google Scholar
• Barlow JL, Bellosi A, Hardman CS, Drynan LF, Wong SH, Cruickshank JP, McKenzie ANJ. Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. J Allergy Clin Immunol. 2012;129:191–8.e1–4.
   PubMed Web of Science ®Google Scholar
• Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev. 2004;202:175–90.
   PubMed Web of Science ®Google Scholar
• Westwick J, Watson ML, White AM, Campbell EM, Smith AW, Uddin J, Yoshimura T. Anti-inflammatory actions of interleukin-13: suppression of tumor necrosis factor-alpha and antigen-induced leukocyte accumulation in the guinea pig lung. Am J Respir Cell Mol Biol. 1999;20:1007–12.
   PubMed Web of Science ®Google Scholar
• Haas CS, Amin MA, Ruth JH, Allen BL, Ahmed S, Pakozdi A, et al. In vivo inhibition of angiogenesis by interleukin-13 gene therapy in a rat model of rheumatoid arthritis. Arthritis Rheum. 2007;56:2535–48.
   PubMed Web of Science ®Google Scholar
• Nishimura Y, Nitto T, Inoue T, Node K. IL-13 attenuates vascular tube formation via JAK2-STAT6 pathway. Circ J. 2008;72:469–75.
   PubMed Web of Science ®Google Scholar
• Isomäki P, Luukkainen R, Toivanen P, Punnonen J. The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis. Arthritis Rheum. 1996;39:1693–702.
   PubMed Web of Science ®Google Scholar
• Marinou I, Till SH, Moore DJ, Wilson AG. Lack of association or interactions between the IL-4, IL-4Ralpha and IL-13 genes, and rheumatoid arthritis. Arthritis Res Ther. 2008;10:R80.
   PubMed Web of Science ®Google Scholar
• Ford R, Tamayo A, Martin B, Niu K, Claypool K, Cabanillas F, Ambrus J. Jr. Identification of B-cell growth factors (interleukin-14; high molecular weight-B-cell growth factors) in effusion fluids from patients with aggressive B-cell lymphomas. Blood. 1995;86:283–93.
   PubMed Web of Science ®Google Scholar
• Leca N, Laftavi M, Shen L, Matteson K, Ambrus J, Pankewycz O. Regulation of human interleukin 14 transcription in vitro and in vivo after renal transplantation. Transplantation. 2008;86:336–41.
   PubMed Web of Science ®Google Scholar
• Peng X, Zhou C, Wei D, Luo Z, Zhang C. Characteristics of a novel monoclonal antibody against interleukin-14alpha. Hybridoma (Larchmt). 2009;28:235–9.
   PubMedGoogle Scholar
• Vámosi G, Bodnár A, Vereb G, Jenei A, Goldman CK, Langowski J, et al. IL-2 and IL-15 receptor alpha-subunits are coexpressed in a supramolecular receptor cluster in lipid rafts of T cells. Proc Natl Acad Sci USA. 2004;101:11082–7.
   PubMed Web of Science ®Google Scholar
• Han KP, Zhu X, Liu B, Jeng E, Kong L, Yovandich JL, et al. IL-15: IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine. 2011;56:804–10.
   PubMed Web of Science ®Google Scholar
• Park JY, Lee SH, Yoon SR, Park YJ, Jung H, Kim TD, Choi I. IL-15-induced IL-10 increases the cytolytic activity of human natural killer cells. Mol Cells. 2011;32:265–72.
   PubMed Web of Science ®Google Scholar
• Correia MP, Costa AV, Uhrberg M, Cardoso EM, Arosa FA. IL-15 induces CD8+ T cells to acquire functional NK receptors capable of modulating cytotoxicity and cytokine secretion. Immunobiology. 2011;216:604–12.
   PubMed Web of Science ®Google Scholar
• Budagian V, Bulanova E, Paus R, Bulfone-Paus S. IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev. 2006;17:259–80.
   PubMed Web of Science ®Google Scholar
• Leong JW, Chase JM, Romee R, Schneider SE, Sullivan RP, Cooper MA, Fehniger TA. Preactivation with IL-12, IL-15, and IL-18 induces cd25 and a functional high-affinity il-2 receptor on human cytokine-induced memory-like natural killer cells. Biol Blood Marrow Transplant. 2014;20:463–73.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Liew FY. Interleukin 15: a proinflammatory role in rheumatoid arthritis synovitis. Immunol Today. 1998;19:75–9.
   PubMedGoogle Scholar
• McInnes IB, Leung BP, Sturrock RD, Field M, Liew FY. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med. 1997;3:189–95.
   PubMed Web of Science ®Google Scholar
• Mcinnes IB, Al Mughales J, Field M, Leung BP. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med. 1996;2:3–5.
   PubMed Web of Science ®Google Scholar
• Halvorsen EH, Strønen E, Hammer HB, Goll GL, Sollid LM. Interleukin-15 induces interleukin-17 production by synovial T cell lines from patients with rheumatoid arthritis. Scand J Immunol. 2011;73:243–9.
   PubMed Web of Science ®Google Scholar
• Hart G, Avin-Wittenberg T, Shachar I. IL-15 regulates immature B-cell homing in an Ly49D-, IL-12, and IL-18 dependent manner. Blood. 2008;111:50–9.
   PubMed Web of Science ®Google Scholar
• Strengell M, Matikainen S, Siren J, Lehtonen A, Foster D, Julkunen I, Sareneva T. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol. 2003;170:5464–9.
   PubMed Web of Science ®Google Scholar
• Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, Maslinski W. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin a-sensitive mechanism. J Immunol. 2000;164:2832–8.
   PubMed Web of Science ®Google Scholar
• Alleva DG, Kaser SB, Monroy MA, Fenton MJ, Beller DI. IL-15 functions as a potent autocrine regulator of macrophage proinflammatory cytokine production: evidence for differential receptor subunit utilization associated with stimulation or inhibition. J Immunol. 1997;159:2941–51.
   PubMed Web of Science ®Google Scholar
• Angiolillo AL, Kanegane H, Sgadari C, Reaman GH, Tosato G. Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun. 1997;233:231–7.
   PubMed Web of Science ®Google Scholar
• Badolato R, Ponzi AN, Millesimo M, Notarangelo LD, Musso T. Interleukin-15 (IL-15) induces IL-8 and monocyte chemotactic protein 1 production in human monocytes. Blood. 1997;90:2804–9.
   PubMed Web of Science ®Google Scholar
• Lugering N, Kucharzik T, Maaser C, Kraft M, Domschke W. Interleukin-15 strongly inhibits interleukin-8 and monocyte chemoattractant protein-1 production in human colonic epithelial cells. Immunology. 1999;98:504–9.
   PubMed Web of Science ®Google Scholar
• Constantinescu CS, Grygar C, Kappos L, Leppert D. Interleukin 15 stimulates production of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by human peripheral blood mononuclear cells. Cytokine. 2001;13:244–7.
   PubMed Web of Science ®Google Scholar
• Tao Y, Qiu X, Xu C, Sun B, Shi C. Expression and correlation of matrix metalloproteinase-7 and interleukin-15 in human osteoarthritis. Int J Clin Exp Pathol. 2015;8:9112–18.
   PubMed Web of Science ®Google Scholar
• Park MK, Her YM, La Cho M, Oh HJ, Park EM, Kwok SK, et al. IL-15 promotes osteoclastogenesis via the PLD pathway in rheumatoid arthritis. Immunol Lett. 2011;139:42–51.
   PubMed Web of Science ®Google Scholar
• Takeda H, Kikuchi T, Soboku K, Okabe I, Mizutani H, Mitani A, et al. Effect of IL-15 and natural killer cells on osteoclasts and osteoblasts in a mouse coculture. Inflammation. 2014;37:657–69.
   PubMed Web of Science ®Google Scholar
• Ogata Y, Kukita A, Kukita T, Komine M, Miyahara A, Miyazaki S, Kohashi O. A novel role of IL-15 in the development of osteoclasts: inability to replace its activity with IL-2. J Immunol. 1999;162:2754–60.
   PubMed Web of Science ®Google Scholar
• Machado Diaz AC, Chico Capote A, Arrieta Aguero CA, Rodríguez Alvarez Y, García del Barco Herrera D, Estévez del Toro M, et al. Proinflammatory soluble interleukin-15 receptor alpha is increased in rheumatoid arthritis. Arthritis. 2012;2012:1–7.
   Google Scholar
• Baslund B, Tvede N, Danneskiold-Samsoe B, Larsson P, Panayi G, Petersen J, et al. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. Arthritis Rheum. 2005;52:2686–92.
   PubMed Web of Science ®Google Scholar
• Cruikshank WW, Center DM, Nisar N, Wu M, Natke B, Theodore AC, Kornfeld H. Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. Proc Natl Acad Sci USA. 1994;91:5109–13.
   PubMed Web of Science ®Google Scholar
• Cruikshank WW, Kornfeld H, Center DM. Interleukin-16. J Leukoc Biol. 2000;67:757–66.
   PubMed Web of Science ®Google Scholar
• Krug N, Cruikshank WW, Tschernig T, Erpenbeck VJ, Balke K, Hohlfeld JM, et al. Interleukin 16 and T-cell chemoattractant activity in bronchoalveolar lavage 24 hours after allergen challenge in asthma. Am J Respir Crit Care Med. 2000;162:105–11.
   PubMed Web of Science ®Google Scholar
• Blaschke S, Schulz H, Schwarz G, Blaschke V, Muller GA, Reuss-Borst M. Interleukin 16 expression in relation to disease activity in rheumatoid arthritis. J Rheumatol. 2001;28:12–21.
   PubMed Web of Science ®Google Scholar
• Klimiuk PA, Coronzy JJ, Weyand CM. IL-16 as an anti-inflammatory cytokine in rheumatoid synovitis. J Immunol. 1999;162:4293–9.
   PubMed Web of Science ®Google Scholar
• Murota A, Suzuki K, Kassai Y, Miyazaki T, Morita R, Kondo Y, et al. Serum proteomic analysis identifies interleukin 16 as a biomarker for clinical response during early treatment of rheumatoid arthritis. Cytokine. 2015;78:87–93.
   PubMed Web of Science ®Google Scholar
• Franz JK, Kolb SA, Hummel KM, Lahrtz F, Neidhart M, Aicher WK, et al. Interleukin-16, produced by synovial fibroblasts, mediates chemoattraction for CD4+ T lymphocytes in rheumatoid arthritis. Eur J Immunol. 1998;28:2661–71.
   PubMed Web of Science ®Google Scholar
• Sharma V, Sparks JL, Vail JD. Human B-cell lines constitutively express and secrete interleukin-16. Immunology. 2000;99:266–71.
   PubMed Web of Science ®Google Scholar
• Rumsaeng V, Cruikshank WW, Foster B, Prussin C, Kirshenbaum AS, Davis TA, et al. Metcalfe, human mast cells produce the CD4+ T lymphocyte chemoattractant factor, IL-16. J Immunol. 1997;159:2904–10.
   PubMed Web of Science ®Google Scholar
• Cruikshank W, Lynch EA, Heijens CA, Horst NF, Center DM. Cutting edge: IL-16/CD4 preferentially induces Th1 cell migration: requirement of CCR5. J Immunol. 2003;171:4965–8.
   PubMed Web of Science ®Google Scholar
• Cho ML, Jung YO, Kim KW, Park MK, Oh HJ, Ju JH, et al. IL-17 induces the production of IL-16 in rheumatoid arthritis. Exp Mol Med. 2008;40:237–45.
   PubMed Web of Science ®Google Scholar
• Skundric DS, Cai J, Cruikshank WW, Gveric D. Production of IL-16 correlates with CD4+ Th1 inflammation and phosphorylation of axonal cytoskeleton in multiple sclerosis lesions. J Neuroinflammation. 2006;3:13.
   PubMed Web of Science ®Google Scholar
• Park SL, Hwang B, Lee SY, Kim WT, Choi YH, Chang YC, et al. p21WAF1 Is required for interleukin-16-induced migration and invasion of vascular smooth muscle cells via the p38MAPK/Sp-1/MMP-9 pathway. PLoS One. 2015;10:e0142153.
   PubMed Web of Science ®Google Scholar
• Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9:556–67.
   PubMed Web of Science ®Google Scholar
• Lohr J, Knoechel B, Wang JJ, Villarino AV, Abbas AK. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med. 2006;203:2785–91.
   PubMed Web of Science ®Google Scholar
• Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009;206:1457–64.
   PubMed Web of Science ®Google Scholar
• Konya C, Paz Z, Apostolidis SA, Tsokos GC. Update on the role of Interleukin 17 in rheumatologic autoimmune diseases. Cytokine. 2015;75:1–9.
   PubMed Web of Science ®Google Scholar
• Stockinger B, Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006;24:179–89.
   PubMed Web of Science ®Google Scholar
• Park JS, Park MK, Lee SY, Oh HJ, Lim MA, Cho WT, et al. TWEAK promotes the production of Interleukin-17 in rheumatoid arthritis. Cytokine. 2012;60:143–9.
   PubMed Web of Science ®Google Scholar
• Mills K, Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity. 2009;31:331–41.
   PubMed Web of Science ®Google Scholar
• Lalor SJ, Dungan LS, Sutton CE, Basdeo SA, Fletcher JM, Mills KHG. Caspase-1–processed cytokines IL-1β and IL-18 promote IL-17 production by γδ and CD4 T cells that mediate autoimmunity. J Immunol. 2011;186:5738–48.
   PubMed Web of Science ®Google Scholar
• Liu X, Ren S, Qu X, Ge C, Cheng K, Zhao RCH. Mesenchymal stem cells inhibit Th17 cells differentiation via IFN-γ-mediated SOCS3 activation. Immunol Res. 2015;61:219–29.
   PubMed Web of Science ®Google Scholar
• Littman DR, Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126:1121–33.
   PubMed Web of Science ®Google Scholar
• Hirota K, Hashimoto M, Yoshitomi H, Tanaka S, Nomura T, Yamaguchi T, et al. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med. 2007;204:41–7.
   PubMed Web of Science ®Google Scholar
• Roeleveld DM, Koenders MI. The role of the Th17 cytokines IL-17 and IL-22 in Rheumatoid Arthritis pathogenesis and developments in cytokine immunotherapy. Cytokine. 2014;74:101–7.
   PubMed Web of Science ®Google Scholar
• Alexandrakis MG, Pappa CA, Miyakis S, Sfiridaki A, Kafousi M, Alegakis A, Stathopoulos EN. Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma. Eur J Intern Med. 2006;17:412–16.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li G, Qian Y, Zhang H, Sunagawa M, Guo S, et al. Interleukin-17A promotes rheumatoid arthritis synoviocytes migration and invasion under hypoxia by increasing MMP2 and MMP9 expression through NF-κB/HIF-1α pathway. Mol Immunol. 2013;53:227–36.
   PubMed Web of Science ®Google Scholar
• Pickens SR, Volin MV, Mandelin AM, Kolls JK, Pope RM, Shahrara S. IL-17 contributes to angiogenesis in rheumatoid arthritis. J Immunol. 2010;184:3233–41.
   PubMed Web of Science ®Google Scholar
• Ito H, Yamada H, Shibata TN, Mitomi H, Nomoto S, Ozaki S. Dual role of interleukin-17 in pannus growth and osteoclastogenesis in rheumatoid arthritis. Arthritis Res Ther. 2011;13:R14.
   PubMed Web of Science ®Google Scholar
• Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJJ, Kolls JK, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol. 2003;170:2655–62.
   PubMed Web of Science ®Google Scholar
• Yago T, Nanke Y, Ichikawa N, Kobashigawa T, Mogi M, Kamatani N, Kotake S. IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17. J Cell Biochem. 2009;108:947–55.
   PubMed Web of Science ®Google Scholar
• Moon YM, Yoon BY, Her YM, Oh HJ, Lee JS, Kim KW, et al. IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis. Arthritis Res Ther. 2012;14:R246.
   PubMed Web of Science ®Google Scholar
• Shen L, Zhang H, Yan T, Zhou G, Liu R. Association between interleukin 17A polymorphisms and susceptibility to rheumatoid arthritis in a Chinese population. Gene. 2015;566:18–22.
   PubMed Web of Science ®Google Scholar
• Kellner H. Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. Ther Adv Musculoskelet Dis. 2013;5:141–52.
   PubMedGoogle Scholar
• Zhu S, Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential. Clin Sci (Lond). 2012;122:487–511.
   PubMed Web of Science ®Google Scholar
• Kikly K, Liu L, Na S, Sedgwick JD. The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr Opin Immunol. 2006;18:670–5.
   PubMed Web of Science ®Google Scholar
• Röhn TA, Jennings GT, Hernandez M, Grest P, Beck M, Zou Y, et al. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol. 2006;36:2857–67.
   PubMed Web of Science ®Google Scholar
• Buckland J. Rheumatoid arthritis: anti-TNF and anti-IL-17 antibodies—better together!. Nat Rev Rheumatol. 2014;10:699.
   PubMedGoogle Scholar
• Debets R, Timans JC, Churakowa T, Zurawski S, de Waal Malefyt R, Moore KW, et al. IL-18 receptors, their role in ligand binding and function: anti-IL-1RAcPL antibody, a potent antagonist of IL-18. J Immunol. 2000;165:4950–6.
   PubMed Web of Science ®Google Scholar
• Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, et al. A proinflammatory role for IL-18 in rheumatoid arthritis. J Clin Invest. 1999;104:1393–401.
   PubMed Web of Science ®Google Scholar
• Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol. 1998;161:3400–7.
   PubMed Web of Science ®Google Scholar
• Sareneva T, Julkunen I, Matikainen S. IFN-alpha and IL-12 induce IL-18 receptor gene expression in human NK and T cells. J Immunol. 2000;165:1933–8.
   PubMed Web of Science ®Google Scholar
• Smeltz RB, Chen J, Hu-Li J, Shevach EM. Regulation of interleukin (IL)-18 receptor alpha chain expression on CD4(+) T cells during T helper (Th)1/Th2 differentiation. Critical downregulatory role of IL-4. J Exp Med. 2001;194:143–53.
   PubMed Web of Science ®Google Scholar
• Enoksson SL, Grasset EK, Hagglof T, Mattsson N, Kaiser Y, Gabrielsson S, et al. PNAS plus: the inflammatory cytokine IL-18 induces self-reactive innate antibody responses regulated by natural killer T cells. Proc Natl Acad Sci. 2011;108:E1399–407.
   PubMed Web of Science ®Google Scholar
• Amin MA, Rabquer BJ, Mansfield PJ, Ruth JH, Marotte H, Haas CS, et al. Interleukin 18 induces angiogenesis in vitro and in vivo via Src and Jnk kinases. Ann Rheum Dis. 2010;69:2204–12.
   PubMed Web of Science ®Google Scholar
• Park CC, Morel JC, Amin MA, Connors MA, Harlow LA, Koch AE. Evidence of IL-18 as a novel angiogenic mediator. J Immunol. 2001;167:1644–53.
   PubMed Web of Science ®Google Scholar
• Amin MA, Mansfield PJ, Pakozdi A, Campbell PL, Ahmed S, Martinez RJ, Koch AE. Interleukin-18 induces angiogenic factors in rheumatoid arthritis synovial tissue fibroblasts via distinct signaling pathways. Arthritis Rheum. 2007;56:1787–97.
   PubMed Web of Science ®Google Scholar
• Volin MV, Koch AE. Interleukin-18: a mediator of inflammation and angiogenesis in rheumatoid arthritis. J Interferon Cytokine Res. 2011;31:745–51.
   PubMed Web of Science ®Google Scholar
• Mallat Z, Silvestre JS, Le Ricousse-Roussanne S, Lecomte-Raclet L, Corbaz A, Clergue M, et al. Interleukin-18/interleukin-18 binding protein signaling modulates ischemia-induced neovascularization in mice hindlimb. Circ Res. 2002;91:441–8.
   PubMed Web of Science ®Google Scholar
• Cao R, Farnebo J, Kurimoto M, Cao Y. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J. 1999;13:2195–202.
   PubMed Web of Science ®Google Scholar
• Kanda N, Shimizu T, Tada Y, Watanabe S. IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. Eur J Immunol. 2007;37:338–50.
   PubMed Web of Science ®Google Scholar
• Ji JD, Lee WJ. Interleukin-18 gene polymorphisms and rheumatoid arthritis: a meta-analysis. Gene. 2013;523:27–32.
   PubMed Web of Science ®Google Scholar
• Della Justina Fariasa T, do Canto LM, Medeiros MD, Rodrigues Sereia AF, de Carlos Back LK, de Mello FM, et al. Lack of association between interleukin-18 polymorphisms and rheumatoid arthritis. Rev Bras Reumatol. 2013;53:199–205.
   PubMed Web of Science ®Google Scholar
• Horwood NJ, Udagawa N, Elliott J, Grail D, Okamura H, Kurimoto M, et al. Interleukin 18 inhibits osteoclast formation via T cell production of granulocyte macrophage colony-stimulating factor. J Clin Invest. 1998;101:595–603.
   PubMed Web of Science ®Google Scholar
• Zhang W, Cong X, Qin YH, He ZW, He DY, Dai S. IL-18 upregulates the production of key regulators of osteoclastogenesis from fibroblast-like synoviocytes in rheumatoid arthritis. Inflammation. 2013;36:103–9.
   PubMed Web of Science ®Google Scholar
• Takei S, Hoshino T, Matsunaga K, Sakazaki Y, Sawada M, Oda H, et al. Soluble interleukin-18 receptor complex is a novel biomarker in rheumatoid arthritis. Arthritis Res Ther. 2011;13:R52.
   PubMed Web of Science ®Google Scholar
• Fantuzzi G, Reed DA, Dinarello CA. IL-12-induced IFN-gamma is dependent on caspase-1 processing of the IL-18 precursor. J Clin Invest. 1999;104:761–7.
   PubMed Web of Science ®Google Scholar
• Liao YC, Liang WG, Chen FW, Hsu JH, Yang JJ, Chang MS. IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol (Baltimore, Md 1950). 2002;169:4288–97.
   PubMed Web of Science ®Google Scholar
• Leng RX, Pan HF, Tao JH, Ye DQ. IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases. Expert Opin Ther Targets. 2011;15:119–26.
   PubMed Web of Science ®Google Scholar
• Parrish-Novak J, Xu W, Brender T, Yao L, Jones C, West J, et al. Interleukins 19, 20, and 24 signal through two distinct receptor complexes: differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem. 2002;277:47517–23.
   PubMed Web of Science ®Google Scholar
• Jain S, Gabunia K, Kelemen SE, Panetti TS, Autieri MV. The anti-inflammatory cytokine interleukin 19 is expressed by and angiogenic for human endothelial cells. Arterioscler Thromb Vasc Biol. 2011;31:167–75.
   PubMed Web of Science ®Google Scholar
• Richards J, Gabunia K, Kelemen SE, Kako F, Choi ET, Autieri MV. Interleukin-19 increases angiogenesis in ischemic hind limbs by direct effects on both endothelial cells and macrophage polarization. J Mol Cell Cardiol. 2015;79:21–31.
   PubMed Web of Science ®Google Scholar
• Gabunia K, Autieri MV. Interleukin-19 can enhance angiogenesis by macrophage polarization. Macrophage. 2015;2:2–5.
   Google Scholar
• Sabat R, Wallace E, Endesfelder S, Wolk K. IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases. Expert Opin Ther Targets. 2007;11:601–12.
   PubMed Web of Science ®Google Scholar
• Heuzé-Vourc’h N, Liu M, Dalwadi H, Baratelli FE, Zhu L, Goodglick L, et al. IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression. Biochem Biophys Res Commun. 2005;333:470–5.
   PubMed Web of Science ®Google Scholar
• Hsieh MY, Chen WY, Jiang MJ, Cheng BC, Huang TY, Chang MS. Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immun. 2006;7:234–42.
   PubMed Web of Science ®Google Scholar
• Kragstrup TW, Otkjaer K, Holm C, Jørgensen A, Hokland M, Iversen L, Deleuran B. The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthropathy. Cytokine. 2008;41:16–23.
   PubMed Web of Science ®Google Scholar
• Hsu YH, Chen WY, Chan CH, Wu CH, Sun ZJ, Chang MS. Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J Exp Med. 2011;208:1849–61.
   PubMed Web of Science ®Google Scholar
• Hsu YH, Wei CC, Shieh DB, Chan CH, Chang MS. Anti-IL-20 monoclonal antibody alleviates inflammation in oral cancer and suppresses tumor growth. Mol Cancer Res. 2012;10:1430–9.
   PubMed Web of Science ®Google Scholar
• Hsu YH, Hsing CH, Li CF, Chan CH, Chang MC, Yan JJ, Chang MS. Anti-IL-20 monoclonal antibody suppresses breast cancer progression and bone osteolysis in murine models. J Immunol. 2012;188:1981–91.
   PubMed Web of Science ®Google Scholar
• Imaoka A, Zhang L, Kuboyama N, Abiko Y. Reduction of IL-20 expression in rheumatoid arthritis by linear polarized infrared light irradiation. Laser Ther. 2014;23:109–14.
   PubMedGoogle Scholar
• Asao H, Okuyama C, Kumaki S, Ishii N, Tsuchiya S, Foster D, Sugamura K. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol. 2001;167:1–5.
   PubMed Web of Science ®Google Scholar
• Mehta DS, Wurster AL, Grusby MJ. Biology of IL-21 and the IL-21 receptor. Immunol Rev. 2004;202:84–95.
   PubMed Web of Science ®Google Scholar
• Habib T, Senadheera S, Weinberg K, Kaushansky K. The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry. 2002;41:8725–31.
   PubMed Web of Science ®Google Scholar
• Frederiksen KS, Lundsgaard D, Freeman JA, Hughes SD, Holm TL, Skrumsager BK, et al. IL-21 induces in vivo immune activation of NK cells and CD8+ T cells in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother. 2008;57:1439–49.
   PubMed Web of Science ®Google Scholar
• Skak K, Frederiksen KS, Lundsgaard D. Interleukin-21 activates human natural killer cells and modulates their surface receptor expression. Immunology. 2008;123:575–83.
   PubMed Web of Science ®Google Scholar
• Perez SA. Effect of IL-21 on NK cells derived from different umbilical cord blood populations. Int Immunol. 2005;18:49–58.
   PubMed Web of Science ®Google Scholar
• Brady J, Hayakawa Y, Smyth MJ, Nutt SL. IL-21 induces the functional maturation of murine NK cells. J Immunol. 2004;172:2048–58.
   PubMed Web of Science ®Google Scholar
• Spolski R, Leonard WJ. Interleukin-21: a double-edged sword with therapeutic potential. Nat Rev Drug Discov. 2014;13:379–95.
   PubMed Web of Science ®Google Scholar
• Deenick EK, Tangye SG. Autoimmunity: IL-21: a new player in Th17-cell differentiation. Immunol Cell Biol. 2007;85:503–5.
   PubMed Web of Science ®Google Scholar
• Wei L, Laurence A, Elias KM, O’Shea JJ. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem. 2007;282:34605–10.
   PubMed Web of Science ®Google Scholar
• Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007;448:480–3.
   PubMed Web of Science ®Google Scholar
• Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, et al. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature. 2008;454:350–2.
   PubMed Web of Science ®Google Scholar
• Korn T, Bettelli E, Gao W, Awasthi A, Jäger A, Strom TB, et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature. 2007;448:484–7.
   PubMed Web of Science ®Google Scholar
• Niu X, He D, Zhang X, Yue T, Li N, Zhang JZ, et al. IL-21 regulates Th17 cells in rheumatoid arthritis. Hum Immunol. 2010;71:334–41.
   PubMed Web of Science ®Google Scholar
• Spolski R, Leonard WJ. IL-21 and T follicular helper cells. Int Immunol. 2010;22:7–12.
   PubMed Web of Science ®Google Scholar
• Ozaki K, Spolski R, Feng CG, Qi C, Cheng J, Sher A, et al. A critical role for IL-21 in regulating immunoglobulin production. Science. 2002;298:1630–4.
   PubMed Web of Science ®Google Scholar
• Ettinger R, Sims GP, Fairhurst AM, Robbins R, da Silva YS, Spolski R, et al. IL-21 Induces differentiation of human naive and memory B cells into antibody-secreting plasma cells. J Immunol. 2005;175:7867–79.
   PubMed Web of Science ®Google Scholar
• Ettinger R, Sims GP, Robbins R, Withers D, Fischer RT, Grammer AC, et al. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol. 2007;178:2872–82.
   PubMed Web of Science ®Google Scholar
• Carbone G, Wilson A, Diehl SA, Bunn J, Cooper SM, Rincon M. Interleukin-6 receptor blockade selectively reduces IL-21 production by CD4 T cells and IgG4 autoantibodies in rheumatoid arthritis. Int J Biol Sci. 2013;9:279–88.
   PubMed Web of Science ®Google Scholar
• Diehl SA, Schmidlin H, Nagasawa M, Blom B, Spits H. IL-6 triggers IL-21 production by human CD4+ T cells to drive STAT3-dependent plasma cell differentiation in B cells. Immunol Cell Biol. 2012;90:802–11.
   PubMed Web of Science ®Google Scholar
• Castermans K, Tabruyn SP, Zeng R, Van Beijnum JR, Eppolito C, Leonard WJ, et al. Angiostatic activity of the antitumor cytokine interleukin-21. Blood. 2008;112:4940–7.
   PubMed Web of Science ®Google Scholar
• Whitters MJ, Konz RF, Young DA, Grusby MJ, Collins M, Dunussi-joannopoulos K, Ma HL. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN- γ. J Immunol. 2012;171:608–15.
   Google Scholar
• Kim KW, Kim HR, Kim BM, La Cho M, Lee SH. Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis. Am J Pathol. 2015;185:3011–24.
   PubMed Web of Science ®Google Scholar
• Kwok SK, La Cho M, Park MK, Oh HJ, Park JS, Her YM, et al. Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis. Arthritis Rheum. 2012;64:740–51.
   PubMed Web of Science ®Google Scholar
• Sglunda O, Mann HF, Hulejová H, Pecha O, Pleštilová L, Růžičková O, et al. Decrease in serum interleukin 21 levels is associated with disease activity improvement in patients with recent-onset rheumatoid arthritis. Physiol Res. 2014;63:475–81.
   PubMed Web of Science ®Google Scholar
• Cho SG. Interleukin 21 blockade modulates activated T- and B-cell homeostasis via B-cell activating factor pathway-mediated inhibition in a murine model of acute graft-versus-host disease. Exp Hematol. 2015;43:23–31.
   Web of Science ®Google Scholar
• Yuan FL, Hu W, Lu WG, Li X, Li JP, Xu RS, et al. Targeting interleukin-21 in rheumatoid arthritis. Mol Biol Rep. 2011;38:1717–21.
   PubMed Web of Science ®Google Scholar
• Xie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J, et al. Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem. 2000;275:31335–9.
   PubMed Web of Science ®Google Scholar
• Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity. 2004;21:241–54.
   PubMed Web of Science ®Google Scholar
• ShangYu W, Zhu J, Zhou L, Chang W, Wang K, Li QM. Blocking IL-22, a potential treatment strategy for adenomyosis by inhibiting crosstalk between vascular endothelial and endometrial stromal cells. Am J Transl Res. 2015;7:1782–97.
   PubMed Web of Science ®Google Scholar
• Barone F, Nayar S, Campos J, Cloake T, Withers DR, Toellner KM, et al. IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs. Proc Natl Acad Sci. 2015;112:11024–9.
   PubMed Web of Science ®Google Scholar
• Ikeuchi H, Kuroiwa T, Hiramatsu N. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum. 2005;52:1037.
   PubMed Web of Science ®Google Scholar
• Yang X, Zheng SG. Interleukin-22: a likely target for treatment of autoimmune diseases. Autoimmun Rev. 2014;13:615–20.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Krueger JG, Lundblad MS, Gothberg M, Skolnick BE. First-in-human, phase 1, randomized, dose-escalation trial with recombinant anti-IL-20 monoclonal antibody in patients with psoriasis. PLoS One. 2015;10:e0134703.
   PubMed Web of Science ®Google Scholar
• Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168:5699–708.
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715–25.
   PubMed Web of Science ®Google Scholar
• Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell. 2009;15:114–23.
   PubMed Web of Science ®Google Scholar
• Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442:461–5.
   PubMed Web of Science ®Google Scholar
• Hamdy G, Darweesh H, Fawzy S, Khattab EA, Fawzy E, Sheta M. Association of interleukin-23 receptor (IL-23R) gene polymorphisms (rs11209026, rs2201841 and rs10889677) with Egyptian rheumatoid arthritis patients, Egypt. Rheumatol. 2015;37:159–63.
   Google Scholar
• Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006;116:1218–22.
   PubMed Web of Science ®Google Scholar
• Abraham C, Cho JH. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease. Annu Rev Med. 2009;60:97–110.
   PubMed Web of Science ®Google Scholar
• Yago T, Nanke Y, Kawamoto M, Furuya T, Kobashigawa T, Kamatani N, Kotake S. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther. 2007;9:R96.
   PubMed Web of Science ®Google Scholar
• Kamiya S, Nakamura C, Fukawa T, Ono K, Ohwaki T, Yoshimoto T, Wada S. Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. J Bone Miner Metab. 2007;25:277–85.
   PubMed Web of Science ®Google Scholar
• Przepiera-Będzak H, Fischer K, Brzosko M. Serum IL-6 and IL-23 levels and their correlation with angiogenic cytokines and disease activity in ankylosing spondylitis, psoriatic arthritis, and SAPHO syndrome. Mediators Inflamm. 2015;2015:1–7.
   Web of Science ®Google Scholar
• Li J, Lau G, Chen L, Yuan YF, Huang J, Luk JM, et al. Interleukin 23 promotes hepatocellular carcinoma metastasis via NF-kappa B induced matrix metalloproteinase 9 expression. PLoS One. 2012;7:e46264.
   Web of Science ®Google Scholar
• Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 2003;198:1951–7.
   PubMed Web of Science ®Google Scholar
• Tang C, Chen S, Qian H, Huang W. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology. 2012;135:112–24.
   PubMed Web of Science ®Google Scholar
• Wang M, Liang P. Interleukin-24 and its receptors. Immunology. 2005;114:166–70.
   PubMed Web of Science ®Google Scholar
• Wang M, Tan Z, Zhang R, Kotenko SV, Liang P. Interleukin 24 (MDA-7/MOB-5) signals through two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2. J Biol Chem. 2002;277:7341–7.
   PubMed Web of Science ®Google Scholar
• Ramesh R, Mhashilkar A, Tanaka M, Saito FY, Branch C, Sieger DK, et al. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res. 2003;63:5105–13.
   PubMed Web of Science ®Google Scholar
• Fisher PB, Sarkar D, Lebedeva IV, Emdad L, Gupta P, Sauane M, et al. Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol. 2007;224:300–7.
   PubMed Web of Science ®Google Scholar
• Li L, Wang ZX, Wang ZH. Combination of IL-24 and cisplatin inhibits cervical cancer growth in a Xenograft nude mice model. Asian Pac J Cancer Prev. 2011;12:3293–8.
   PubMedGoogle Scholar
• Sauane M, Gopalkrishnan RV, Sarkar D, Su ZZ, Lebedeva IV, Dent P, et al. MDA-7/IL-24: novel cancer growth suppressing and apoptosis inducing cytokine. Cytokine Growth Factor Rev. 2003;14:35–51.
   PubMed Web of Science ®Google Scholar
• Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, et al. IL-25 Induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity. 2001;15:985–95.
   PubMed Web of Science ®Google Scholar
• Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006;8:S3.
   PubMed Web of Science ®Google Scholar
• Wong CK, Cheung PFY, Ip WK, Lam CWK. Interleukin-25-induced chemokines and interleukin-6 release from eosinophils is mediated by p38 mitogen-activated protein kinase, c-Jun N-terminal kinase, and nuclear factor-kappaB. Am J Respir Cell Mol Biol. 2005;33:186–94.
   PubMed Web of Science ®Google Scholar
• Corrigan CJ, Wang W, Meng Q, Fang C, Eid G, Caballero MR, et al. Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses. J Allergy Clin Immunol. 2011;128:119–24.
   Web of Science ®Google Scholar
• Tamachi T, Maezawa Y, Ikeda K, Iwamoto I, Nakajima H. Interleukin 25 in allergic airway inflammation. Int Arch Allergy Immunol. 2006;140:59–62.
   PubMed Web of Science ®Google Scholar
• Tang W, Smith SG, Beaudin S, Dua B, Howie K, Gauvreau G, O’Byrne PM. IL-25 and IL-25 receptor expression on eosinophils from subjects with allergic asthma. Int Arch Allergy Immunol. 2014;163:5–10.
   PubMed Web of Science ®Google Scholar
• Maezawa Y, Nakajima H, Suzuki K, Tamachi T, Ikeda K, Inoue J, et al. Involvement of TNF receptor-associated factor 6 in IL-25 receptor signaling. J Immunol. 2006;176:1013–18.
   PubMed Web of Science ®Google Scholar
• Hällgren R, Feltelius N, Svenson N, Venge KP. Eosinophil involvement in rheumatoid arthritis as reflected by elevated serum levels of eosinophil cationic protein. Clin Exp Immunol. 1985;59:539–46.
   PubMed Web of Science ®Google Scholar
• Knappe A, Hör S, Wittmann S, Fickenscher H. Induction of a novel cellular homolog of interleukin-10, AK155, by transformation of T lymphocytes with herpesvirus saimiri. J Virol. 2000;74:3881–7.
   PubMed Web of Science ®Google Scholar
• Hör S, Pirzer H, Dumoutier L, Bauer F, Wittmann S, Sticht H, et al. The T-cell lymphokine interleukin-26 targets epithelial cells through the interleukin-20 receptor 1 and interleukin-10 receptor 2 chains. J Biol Chem. 2004;279:33343–51.
   PubMed Web of Science ®Google Scholar
• Sheikh F, Baurin VV, Lewis-Antes A, Shah NK, Smirnov SV, Anantha S, et al. Cutting edge: IL-26 signals through a novel receptor complex composed of IL-20 receptor 1 and IL-10 receptor 2. J Immunol. 2004;172:2006–10.
   PubMed Web of Science ®Google Scholar
• Corvaisier M, Delneste Y, Jeanvoine H, Preisser L, Blanchard S, Garo E, et al. IL-26 Is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation. PLoS Biol. 2012;10:e1001395.
   PubMed Web of Science ®Google Scholar
• Donnelly RP, Sheikh F, Dickensheets H, Savan R, Young HA, Walter MR. Interleukin-26: an IL-10-related cytokine produced by Th17 cells. Cytokine Growth Factor Rev. 2010;21:393–401.
   PubMed Web of Science ®Google Scholar
• Meller S, Di Domizio J, Voo KS, Friedrich HC, Chamilos G, Ganguly D, et al. TH17 cells promote microbial killing and innate immune sensing of DNA via interleukin 26. Nat Immunol. 2015;16:970–9.
   PubMed Web of Science ®Google Scholar
• Phillips RAK, McClanahan TK, De Waal R, Rosales M, Vaisberg E, Bazan JF, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol. 2004;172:2225–31.
   PubMed Web of Science ®Google Scholar
• Wang H, Li Z, Yang B, Yu S, Wu C. IL-27 suppresses the production of IL-22 in human CD4(+) T cells by inducing the expression of SOCS1. Immunol Lett. 2013;152:96–103.
   PubMed Web of Science ®Google Scholar
• Owaki T, Asakawa M, Kamiya S, Takeda K, Fukai F, Mizuguchi J, et al. IL-27 suppresses CD28-medicated IL-2 production through suppressor of cytokine signaling 3. J Immunol. 2006;176:2773–80.
   PubMed Web of Science ®Google Scholar
• Murugaiyan G, Mittal A, Lopez-Diego R, Maier LM, Anderson DE, Weiner HL. IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. J Immunol. 2009;183:2435–43.
   PubMed Web of Science ®Google Scholar
• Young A, Linehan E, Hams E, O’Hara Hall AC, McClurg A, Johnston JA, et al. Cutting edge: suppression of GM-CSF expression in murine and human T cells by IL-27. J Immunol. 2012;189:2079–83.
   PubMed Web of Science ®Google Scholar
• Batten M, Kljavin NM, Li J, Walter MJ, de Sauvage FJ, Ghilardi N. Cutting edge: IL-27 is a potent inducer of IL-10 but not FoxP3 in murine T cells. J Immunol. 2008;180:2752–6.
   PubMed Web of Science ®Google Scholar
• Kalliolias GD, Gordon RA, Ivashkiv LB. Suppression of TNF-α and IL-1 signaling identifies a mechanism of homeostatic regulation of macrophages by IL-27. J Immunol. 2010;185:7047–56.
   PubMed Web of Science ®Google Scholar
• Pflanz S, Timans JC, Cheung J, Rosales R, Kanzler H, Gilbert J, et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity. 2002;16:779–90.
   PubMed Web of Science ®Google Scholar
• Lucas S, Ghilardi N, Li J, de Sauvage FJ. IL-27 regulates IL-12 responsiveness of naive CD4+ T cells through Stat1-dependent and -independent mechanisms. Proc Natl Acad Sci USA. 2003;100:15047–52.
   PubMed Web of Science ®Google Scholar
• Kamiya S, Owaki T, Morishima N, Fukai F, Mizuguchi J, Yoshimoto T. An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells. J Immunol. 2004;173:3871–7.
   PubMed Web of Science ®Google Scholar
• Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000;100:655–69.
   PubMed Web of Science ®Google Scholar
• Huber M, Steinwald V, Guralnik A, Brüstle A, Kleemann P, Rosenplänter C, et al. IL-27 inhibits the development of regulatory T cells via STAT3. Int Immunol. 2008;20:223–34.
   PubMed Web of Science ®Google Scholar
• Hall AO, Beiting DP, Tato C, John B, Oldenhove G, Lombana CG, et al. The cytokines interleukin 27 and interferon-γ promote distinct Treg cell populations required to limit infection-induced pathology. Immunity. 2012;37:511–23.
   PubMed Web of Science ®Google Scholar
• Diveu C, McGeachy MJ, Boniface K, Stumhofer JS, Sathe M, Joyce-Shaikh B, et al. IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells. J Immunol. 2009;182:5748–56.
   PubMed Web of Science ®Google Scholar
• Moon SJ, Park JS, Heo YJ, Kang CM, Kim EK, Lim MA, et al. In vivo action of IL-27: reciprocal regulation of Th17 and Treg cells in collagen-induced arthritis. Exp Mol Med. 2013;45:e46.
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Takeda A, Hamano S, Miyazaki Y, Kinjyo I, Ishibashi T, et al. Two-sided roles of IL-27: induction of Th1 differentiation on naive CD4+ T cells versus suppression of proinflammatory cytokine production including IL-23-induced IL-17 on activated CD4+ T cells partially through STAT3-dependent mechanism. J Immunol. 2006;177:5377–85.
   PubMed Web of Science ®Google Scholar
• Ye ZJ, Xu LL, Zhou Q, Cui A, Wang XJ, Zhai K, et al. Recruitment of IL-27-producing CD4+ T cells and effect of IL-27 on pleural mesothelial cells in tuberculous pleurisy. Lung. 2015;193:539–48.
   PubMed Web of Science ®Google Scholar
• Morandi F, Di Carlo E, Ferrone S, Pistoia V, Airoldi I, Petretto A. IL-27 in human secondary lymphoid organs attracts myeloid dendritic cells and impairs HLA class I-restricted antigen presentation. J Immunol. 2014;192:2634–42.
   PubMed Web of Science ®Google Scholar
• Kamiya S, Okumura M, Chiba Y, Fukawa T, Nakamura C, Nimura N, et al. IL-27 suppresses RANKL expression in CD4+ T cells in part through STAT3. Immunol Lett. 2011;138:47–53.
   PubMed Web of Science ®Google Scholar
• Furukawa M, Takaishi H, Takito J, Yoda M, Sakai S, Hikata T, et al. IL-27 abrogates receptor activator of NF- B ligand-mediated osteoclastogenesis of human granulocyte-macrophage colony-forming unit cells through STAT1-dependent inhibition of c-Fos. J Immunol. 2009;183:2397–406.
   PubMed Web of Science ®Google Scholar
• Kalliolias GD, Zhao B, Triantafyllopoulou A, Park-Min KH, Ivashkiv LB. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum. 2010;62:402–13.
   PubMed Web of Science ®Google Scholar
• Liu L, Wang S, Shan B, Shao L, Sato A, Kawamura K, et al. IL-27-mediated activation of natural killer cells and inflammation produced antitumour effects for human oesophageal carcinoma cells. Scand J Immunol. 2008;68:22–9.
   PubMed Web of Science ®Google Scholar
• Giuliani N, Airoldi I. Novel insights into the role of interleukin-27 and interleukin-23 in human malignant and normal plasma cells. Clin Cancer Res. 2011;17:6963–70.
   PubMed Web of Science ®Google Scholar
• Kachroo P, Lee MH, Zhang L, Baratelli F, Lee G, Srivastava MK, et al. IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer. J Exp Clin Cancer Res. 2013;32:97.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Shimamura M, Owaki T, Asakawa M, Fujita K, Kudo M, et al. Antiangiogenic and antitumor activities of IL-27. J Immunol. 2006;176:7317–24.
   PubMed Web of Science ®Google Scholar
• Wong CK, Chen DP, Tam LS, Li EK, Yin YB, Lam CWK. Effects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther. 2010;12:R129.
   PubMed Web of Science ®Google Scholar
• Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4:63–8.
   PubMed Web of Science ®Google Scholar
• Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol. 2005;289:G960–8.
   PubMed Web of Science ®Google Scholar
• Witte K, Witte E, Sabat R, Wolk K. IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev. 2010;21:237–51.
   PubMed Web of Science ®Google Scholar
• Uzé G, Monneron D. IL-28 and IL-29: newcomers to the interferon family. Biochimie. 2007;89:729–34.
   PubMed Web of Science ®Google Scholar
• Dolganiuc A, Kodys K, Marshall C, Saha B, Zhang S, Bala S, Szabo G. Type III interferons, IL-28 and IL-29, are increased in chronic HCV infection and induce myeloid dendritic cell-mediated FoxP3+ regulatory T cells. PLoS One. 2012;7:e44915.
   PubMed Web of Science ®Google Scholar
• Xu L, Feng X, Tan W, Gu W, Guo D, Zhang M, Wang F. IL-29 enhances Toll-like receptor-mediated IL-6 and IL-8 production by the synovial fibroblasts from rheumatoid arthritis patients. Arthritis Res Ther. 2013;15:R170.
   PubMed Web of Science ®Google Scholar
• Xu D, Yan S, Wang H, Gu B, Sun K, Yang X, et al. IL-29 enhances LPS/TLR4-mediated inflammation in rheumatoid arthritis. Cell Physiol Biochem. 2015;37:27–34.
   PubMed Web of Science ®Google Scholar
• Liu X, Wang Z, Ye N, Chen Z, Zhou X, Teng X, et al. A protective role of IL-30 via STAT and ERK signaling pathways in macrophage-mediated inflammation. Biochem Biophys Res Commun. 2013;435:306–12.
   PubMed Web of Science ®Google Scholar
• Garbers C, Spudy B, Aparicio-Siegmund S, Waetzig GH, Sommer J, Holscher C, et al. An lnterleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer. J Biol Chem. 2013;288:4346–54.
   PubMed Web of Science ®Google Scholar
• Dibra D, Cutrera JJ, Li S. Coordination between TLR9 signaling in macrophages and CD3 signaling in T cells induces robust expression of IL-30. J Immunol. 2012;188:3709–15.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Putheti P, Zhou Q, Liu Q, Gao W. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev. 2008;19:347–56.
   PubMed Web of Science ®Google Scholar
• Bilsborough J, Mudri S, Chadwick E, Harder B, Dillon SR. IL-31 receptor (IL-31RA) knockout mice exhibit elevated responsiveness to oncostatin M. J Immunol. 2010;185:6023–30.
   PubMed Web of Science ®Google Scholar
• Broxmeyer HE, Li J, Hangoc G, Cooper S, Tao W, Mantel C, et al. Regulation of myeloid progenitor cell proliferation/survival by IL-31 receptor and IL-31. Exp Hematol. 2007;35:78–86.
   PubMed Web of Science ®Google Scholar
• Perrigoue JG, Li J, Zaph C, Goldschmidt M, Scott P, de Sauvage FJ, et al. IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung. J Exp Med. 2007;204:481–7.
   PubMed Web of Science ®Google Scholar
• Yagi Y, Andoh A, Nishida A, Shioya M, Nishimura T, Hashimoto T, et al. Interleukin-31 stimulates production of inflammatory mediators from human colonic subepithelial myofibroblasts. Int J Mol Med. 2007;19:941–6.
   PubMed Web of Science ®Google Scholar
• Castellani ML, Felaco P, Galzio RJ, Tripodi D, Toniato E, De Lutiis MA, et al. IL-31 a TH2 cytokine involved in immunity and inflammation. Int J Immunopathol Pharmacol. 2010;23:709–13.
   PubMed Web of Science ®Google Scholar
• Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell SR, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5:752–60.
   PubMed Web of Science ®Google Scholar
• Ip WK, Wong CK, Li ML, Li PW, Cheung PF, Lam CW. Interleukin-31 induces cytokine and chemokine production from human bronchial epithelial cells through activation of mitogen-activated protein kinase signalling pathways: implications for the allergic response. Immunology. 2007;122:532–41.
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De Martinis M, Ciccarelli F, Saitta S, Imbesi S, Mannucci C, Gangemi S. Increased levels of interleukin 31 (IL-31) in osteoporosis. BMC Immunol. 2015;16:60.
   PubMed Web of Science ®Google Scholar
• Stott B, Lavender P, Lehmann S, Pennino D, Durham S, Schmidt-Weber CB. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation. J Allergy Clin Immunol. 2013;132:446–54.
   PubMed Web of Science ®Google Scholar
• Kasraie S, Niebuhr M, Werfel T. Interleukin (IL)-31 induces pro-inflammatory cytokines in human monocytes and macrophages following stimulation with staphylococcal exotoxins. Allergy. 2010;65:712–21.
   PubMed Web of Science ®Google Scholar
• Nobbe S, Dziunycz P, Mühleisen B, Bilsborough J, Dillon SR, French LE, Hofbauer GFL. IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis. Acta Derm Venereol. 2012;92:24–8.
   PubMed Web of Science ®Google Scholar
• Yu JI, Park YR, Lee SS, Chae SC. Polymorphisms of interleukin-31 are associated with anti-CCP levels in females with rheumatoid arthritis. J Genet. 2014;93:813–17.
   PubMed Web of Science ®Google Scholar
• Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005;22:131–42.
   PubMed Web of Science ®Google Scholar
• Shoda H, Fujio K, Yamaguchi Y, Okamoto A, Sawada T, Kochi Y, Yamamoto K. Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther. 2006;8:R166.
   PubMed Web of Science ®Google Scholar
• Lee SW, Park HJ, Lee KS, Park SH, Kim S, Jeon SH, Hong S. IL32γ activates natural killer receptor-expressing innate immune cells to produce IFNγ via dendritic cell-derived IL12. Biochem Biophys Res Commun. 2015;461:86–94.
   PubMed Web of Science ®Google Scholar
• Nold-Petry CA, Nold MF, Zepp JA, Kim SH, Voelkel NF, Dinarello CA. IL-32-dependent effects of IL-1beta on endothelial cell functions. Proc Natl Acad Sci USA. 2009;106:3883–8.
   PubMed Web of Science ®Google Scholar
• Suga H, Sugaya M, Miyagaki T, Kawaguchi M, Fujita H, Asano Y, et al. The role of IL-32 in cutaneous T-cell lymphoma. J Invest Dermatol. 2014;134:1428–35.
   PubMed Web of Science ®Google Scholar
• Turner-Brannen E, Choi KG, Arsenault R, El-Gabalawy H, Napper S, Mookherjee N. Inflammatory cytokines IL-32 and IL-17 have common signaling intermediates despite differential dependence on TNF-receptor 1. J Immunol. 2011;186:7127–35.
   PubMed Web of Science ®Google Scholar
• Kang J, Cho M, Kim J, Kim S. A proinflammatory cytokine interleukin- 32beta promotes the production of an anti-inflammatory cytokine interleukin-10. Immunology. 2009;128:e532–40.
   Web of Science ®Google Scholar
• Mabilleau G, Sabokbar A. Interleukin-32 promotes osteoclast differentiation but not osteoclast activation. PLoS One. 2009;4:e4173.
   PubMed Web of Science ®Google Scholar
• Kim YG, Lee CK, Oh JS, Kim SH, Kim KA, Yoo B. Effect of interleukin-32gamma on differentiation of osteoclasts from CD14+ monocytes. Arthritis Rheum. 2010;62:515–23.
   PubMed Web of Science ®Google Scholar
• Meyer N. IL-32, a negative regulator of angiogenesis in chronic airway diseases. J Vasc Med Surg. 2013;1:6925.
   Google Scholar
• Nold-Petry CA, Rudloff I, Baumer Y, Ruvo M, Marasco D, Botti P, et al. IL-32 promotes angiogenesis. J Immunol. 2014;192:589–602.
   PubMed Web of Science ®Google Scholar
• Joosten LAB, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TRD, et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA. 2006;103:3298–303.
   PubMed Web of Science ®Google Scholar
• Liu X, Hammel M, He Y, Tainer JA, Jeng U, Zhang L, et al. Structural insights into the interaction of IL-33 with its receptors. Proc Natl Acad Sci USA. 2013;110:14918–23.
   PubMed Web of Science ®Google Scholar
• Lingel A, Weiss TM, Niebuhr M, Pan B, Appleton BA, Wiesmann C, et al. The structure of interleukin-33 and its interaction with the ST2 and IL-1RAcP receptors—insight into the arrangement of heterotrimeric interleukin-1 signaling complexes. Structure. 2009;17:1398–410.
   PubMed Web of Science ®Google Scholar
• Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pflanz S, Kastelein RA. IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol. 2007;179:2551–5.
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, Mcclanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–90.
   PubMed Web of Science ®Google Scholar
• Jiang HR, Milovanović M, Allan D, Niedbala W, Besnard AG, Fukada SY, et al. IL-33 attenuates EAE by suppressing IL-17 and IFN-γ production and inducing alternatively activated macrophages. Eur J Immunol. 2012;42:1804–14.
   PubMed Web of Science ®Google Scholar
• Allakhverdi Z, Smith DE, Comeau MR, Delespesse G. Cutting edge: the ST2 ligand IL-33 potently activates and drives maturation of human mast cells. J Immunol. 2007;179:2051–4.
   PubMed Web of Science ®Google Scholar
• Komai-koma M, Xu D, Li Y, Mckenzie ANJ. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol. 2007;37:2779–86.
   PubMed Web of Science ®Google Scholar
• Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol. 2008;121:1484–90.
   PubMed Web of Science ®Google Scholar
• Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, et al. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA. 2007;104:282–7.
   PubMed Web of Science ®Google Scholar
• Oboki K, Ohno T, Kajiwara N, Arae K, Morita H, Ishii A, et al. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc Natl Acad Sci USA. 2010;107:18581–6.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Chen G. Role of IL-33 and its receptor in T cell-mediated autoimmune diseases. Biomed Res Int. 2014;2014:587376.
   PubMed Web of Science ®Google Scholar
• Saidi S, Bouri F, Lencel P, Duplomb L, Baud’huin M, Delplace S, et al. IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. Cytokine. 2011;53:347–54.
   PubMed Web of Science ®Google Scholar
• Zaiss MM, Kurowska-Stolarska M, Böhm C, Gary R, Scholtysek C, Stolarski B, et al. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss. J Immunol. 2011;186:6097–105.
   PubMed Web of Science ®Google Scholar
• Schulze J, Bickert T, Beil FT, Zaiss MM, Albers J, Wintges K, et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J Bone Miner Res. 2011;26:704–17.
   PubMed Web of Science ®Google Scholar
• Lima ILA, Macari S, Madeira MFM, Rodrigues LFD, Colavite PM, Garlet GP, et al. Osteoprotective effects of IL-33/ST2 link to osteoclast apoptosis. Am J Pathol. 2015;185:3338–48.
   PubMed Web of Science ®Google Scholar
• Xiangyang Z, Lutian Y, Lin Z, Liping X, Hui S, Jing L. Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis. Cytokine. 2012;58:6–9.
   PubMed Web of Science ®Google Scholar
• Xu D, Jiang H, Li Y, Pushparaj PN, Kurowska-Stolarska M, Leung BP, et al. IL-33 exacerbates autoantibody-induced arthritis. J Immunol. 2010;184:2620–6.
   PubMed Web of Science ®Google Scholar
• Xu D, Jiang H, Kewin P, Li Y, Mu R, Fraser AR, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci USA. 2008;105:10913–18.
   PubMed Web of Science ®Google Scholar
• SayedAli O, Ismail M, Khalifa AM. Levels of interleukin 33 and interleukin 27 in rheumatoid arthritis and osteoarthritis Egyptian patients. Int J Adv Biotechnol Res. 2014;5:465–73.
   Google Scholar
• Hong Y, Moon S, Joo YB, Jeon CH, Cho M, Ju JH, et al. Measurement of interleukin-33 (IL-33) and IL-33 receptors (sST2 and ST2L) in patients with rheumatoid arthritis. J Korean Med Sci. 2011;26:1132.
   PubMed Web of Science ®Google Scholar
• Donnell CO, Mahmoud A, Keane J, Murphy C, White D, Carey S, et al. An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer. Br J Cancer. 2016;114:37–43.
   PubMed Web of Science ®Google Scholar
• Choi Y, Choi H, Min J, Pyun B, Maeng Y, Park H, et al. ST2/TRAF6-mediated endothelial nitric oxide production Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood. 2009;114:3117–26.
   PubMed Web of Science ®Google Scholar
• Stojkovic S, Kaun C, Heinz M, Krychtiuk KA, Rauscher S, Lemberger CE, et al. Interleukin-33 induces urokinase in human endothelial cells―possible impact on angiogenesis. J Thromb Haemost. 2014;12:948–57.
   PubMed Web of Science ®Google Scholar
• Kamradt T, Drube S. A complicated liaison: IL-33 and IL-33R in arthritis pathogenesis. Arthritis Res Ther. 2013;15:115.
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Petra AI, Taracanova A, Panagiotidou S, Conti P. Targeting IL-33 in autoimmunity and inflammation. J Pharmacol Exp Ther. 2015;354:24–31.
   PubMed Web of Science ®Google Scholar
• Chihara T, Suzu S, Hassan R, Chutiwitoonchai N, Hiyoshi M, Motoyoshi K, et al. IL-34 and M-CSF share the receptor Fms but are not identical in biological activity and signal activation. Cell Death Differ. 2010;17:1917–27.
   PubMed Web of Science ®Google Scholar
• Foucher ED, Blanchard S, Preisser L, Garo E, Ifrah N, Guardiola P, et al. IL-34 Induces the differentiation of human monocytes into immunosuppressive macrophages. Antagonistic effects of GM-CSF and IFNγ. PLoS One. 2013;8:e56045.
   PubMed Web of Science ®Google Scholar
• Wei S, Nandi S, Chitu V, Yeung YG, Yu W, Huang M, et al. Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J Leukoc Biol. 2010;88:495–505.
   PubMed Web of Science ®Google Scholar
• Wang Y, Szretter KJ, Vermi W, Gilfillan S, Rossini C, Cella M, et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol. 2012;13:753–60.
   PubMed Web of Science ®Google Scholar
• Bézie S, Picarda E, Ossart J, Tesson L, Usal C, Renaudin K, et al. IL-34 is a Treg-specific cytokine and mediates transplant tolerance. J Clin Invest. 2015;125:3952–64.
   PubMed Web of Science ®Google Scholar
• Boström EA, Lundberg P. The newly discovered cytokine IL-34 is expressed in gingival fibroblasts, shows enhanced expression by pro-inflammatory cytokines, and stimulates osteoclast differentiation. PLoS One. 2013;8:e81665.
   PubMed Web of Science ®Google Scholar
• Hwang SJ, Choi B, Kang SS, Chang JH, Kim YG, Chung YH, et al. Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis. Arthritis Res Ther. 2012;14:R14.
   PubMed Web of Science ®Google Scholar
• Chen Z, Buki K, Vääräniemi J, Gu G, Väänänen HK. The critical role of IL-34 in osteoclastogenesis. PLoS One. 2011;6:e18689.
   PubMed Web of Science ®Google Scholar
• Baud’Huin M, Renault R, Charrier C, Riet A, Moreau A, Brion R, et al. Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis. J Pathol. 2010;221:77–86.
   PubMed Web of Science ®Google Scholar
• Ségaliny AI, Mohamadi A, Dizier B, Lokajczyk A, Brion R, Lanel R, et al. Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer. 2015;137:73–85.
   PubMed Web of Science ®Google Scholar
• Balogh E, Connolly M, Biniecka M, McCormick J, Veale DJ, Fearon U. Interleukin-34 regulates angiogenesis and cell proliferation in inflammatory arthritis, this effect is potentiated by hypoxia. Arthritis Rheum. 2013;65:946.
   Google Scholar
• Chemel M, Le Goff B, Brion R, Cozic C, Berreur M, Amiaud J, et al. Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients. Ann Rheum Dis. 2012;71:150–4.
   PubMed Web of Science ®Google Scholar
• Atef M, Saber N, Aziz DA. Joint destruction and osteoporosis are associated with upregulation of IL34 and cathepsin k expression in rheumatoid arthritis. Clinical trial with anti TNF ñ therapy. J Arthritis. 2015;4:167.
   PubMedGoogle Scholar
• Masteller EL, Wong BR. Targeting IL-34 in chronic inflammation. Drug Discov Today. 2014;19:1212–16.
   PubMed Web of Science ®Google Scholar
• Collison LW, Delgoffe GM, Guy CS, Vignali KM, Chaturvedi V, Fairweather D, et al. The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol. 2012;13:290–9.
   PubMed Web of Science ®Google Scholar
• Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010;11:1093–101.
   PubMed Web of Science ®Google Scholar
• Castellani M, Anogeianaki L, Felaco A, Toniato PE, De Lutiis M, Shaik A, et al. IL-35, an anti-inflammatory cytokine which expands CD4 + CD25+ Treg Cells. J Biol Regul Homeost Agents. 2010;24:131–5.
   PubMed Web of Science ®Google Scholar
• Kochetkova I, Golden S, Holderness K, Callis G, Pascual DW. IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol. 2010;184:7144–53.
   PubMed Web of Science ®Google Scholar
• Whitehead GS, Wilson RH, Nakano K, Burch LH, Nakano H, Cook DN. IL-35 production by inducible costimulator (ICOS)–positive regulatory T cells reverses established IL-17–dependent allergic airways disease. J Allergy Clin Immunol. 2012;129:207–15.e1–5.
   PubMed Web of Science ®Google Scholar
• Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature. 2007;450:566–9.
   PubMed Web of Science ®Google Scholar
• Li X, Mai J, Virtue A, Yin Y, Gong R, Sha X, et al. IL-35 is a novel responsive anti-inflammatory cytokine—a new system of categorizing anti-inflammatory cytokines. PLoS One. 2012;7:e33628.
   Web of Science ®Google Scholar
• Olson BM, Sullivan JA, Burlingham WJ. Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance. Front Immunol. 2013;4:315.
   PubMed Web of Science ®Google Scholar
• Wang R, Yu C, Dambuza IM, Mahdi RM, Dolinska M, Sergeey YV, et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med. 2014;20:633–41.
   PubMed Web of Science ®Google Scholar
• Ning-Wei Z. Interleukin (IL)-35 is raising our expectations. Rev Med Chil. 2010;138:758–66.
   PubMed Web of Science ®Google Scholar
• Choi J, Leung PSC, Bowlus C, Gershwin ME. IL-35 and autoimmunity: a comprehensive perspective. Clin Rev Allergy Immunol. 2015;49:327–32.
   PubMed Web of Science ®Google Scholar
• Saha SS, Singh D, Raymond EL, Ganesan R, Caviness G, Grimaldi C, et al. Signal transduction and intracellular trafficking by the interleukin 36 receptor. J Biol Chem. 2015;290:23997–4006.
   PubMed Web of Science ®Google Scholar
• Dietrich D, Gabay C. Inflammation: IL-36 has proinflammatory effects in skin but not in joints. Nat Rev Rheumatol. 2014;10:639–40.
   PubMed Web of Science ®Google Scholar
• Foster AM, Baliwag J, Chen CS, Guzman AM, Stoll SW, Gudjonsson JE, et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J Immunol. 2014;192:6053–61.
   PubMed Web of Science ®Google Scholar
• Conde J, Scotece M, Abella V, Lopez V, Lazzaro V, Pino J, et al. IL-36alpha: a novel cytokine involved in the inflammatory response in human chondrocytes. Osteoarthr Cartil. 2014;22:S289.
   Web of Science ®Google Scholar
• Carrier Y, Ma HL, Ramon HE, Napierata L, Small C, O’Toole M, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol. 2011;131:2428–37.
   PubMed Web of Science ®Google Scholar
• Lamacchia C, Palmer G, Rodriguez E, Martin P, Vigne S, Seemayer CA, et al. The severity of experimental arthritis is independent of IL-36 receptor signaling. Arthritis Res Ther. 2013;15:R38.
   PubMed Web of Science ®Google Scholar
• Derer A, Groetsch B, Harre U, Bohm C, Towne J, Schett G, et al. Blockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis. PLoS One. 2014;9:2–8.
   Web of Science ®Google Scholar
• Boraschi D, Lucchesi D, Hainzl S, Leitner M, Maier E, Mangelberger D, et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family. Eur Cytokine Netw. 2011;22:127–47.
   PubMed Web of Science ®Google Scholar
• Nold MF, Nold-Petry CA, Zepp JA, Palmer BE, Bufler P, Dinarello CA. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 2010;11:1014–22.
   PubMed Web of Science ®Google Scholar
• Bulau AM, Nold MF, Li S, Nold-Petry CA, Fink M, Mansell A, et al. Role of caspase-1 in nuclear translocation of IL-37, release of the cytokine, and IL-37 inhibition of innate immune responses. Proc Natl Acad Sci USA. 2014;111:2650–5.
   PubMed Web of Science ®Google Scholar
• Li S, Neff CP, Barber K, Hong J, Luo Y, Azam T, et al. Extracellular forms of IL-37 inhibit innate inflammation in vitro and in vivo but require the IL-1 family decoy receptor IL-1R8. Proc Natl Acad Sci USA. 2015;112:2497–502.
   PubMed Web of Science ®Google Scholar
• Xu S, Li W, Tong Y, Dong N, Sheng Z, Yao Y. Expression of IL-37 contributes to the immunosuppressive property of human CD4 + CD25 + regulatory T cells. Sci Rep. 2015;28:14478.
   Google Scholar
• Zeng M, Dang W, Chen B, Qing Y, Xie W, Zhao M, Zhou J. IL-37 inhibits the production of pro-inflammatory cytokines in MSU crystal-induced inflammatory response. Clin Rheumatol. 2015;35:2251–8.
   PubMed Web of Science ®Google Scholar
• Xu WD, Zhao Y, Liu Y. Insights into IL-37, the role in autoimmune diseases. Autoimmun Rev. 2015;14:1170–5.
   PubMed Web of Science ®Google Scholar
• Ye L, Huang Z. IL-37 restrains autoimmune diseases. Oncotarget. 2015;6:21775–6.
   PubMed Web of Science ®Google Scholar
• Clavel G, Thiolat A, Boissier MC. Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38, Jt. Joint Bone Spine. 2013;80:449–53.
   PubMed Web of Science ®Google Scholar
• Al-Saadany HM, Hussein MS, Gaber RA, Zaytoun HA. Th-17 cells and serum IL-17 in rheumatoid arthritis patients: correlation with disease activity and severity. Egypt Rheumatol. 2016;38:1–7.
   Web of Science ®Google Scholar
• Xia T, Zheng X, Qian B, Fang H, Wang J, Zhang L, et al. Plasma interleukin-37 is elevated in patients with rheumatoid arthritis: its correlation with disease activity and Th1/Th2/Th17-related cytokines. Dis Markers. 2015;2015:1–6.
   Web of Science ®Google Scholar
• Zhao PW, Jiang WG, Wang L, Jiang ZY, Shan YX, Jiang YF. Plasma levels of IL-37 and correlation with TNF-α, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis. PLoS One. 2014;9:e95346.
   PubMed Web of Science ®Google Scholar
• Xia L, Shen H, Lu J. Elevated serum and synovial fluid levels of interleukin-37 in patients with rheumatoid arthritis: attenuated the production of inflammatory cytokines. Cytokine. 2015;76:553–7.
   PubMed Web of Science ®Google Scholar
• Ge G, Wang A, Yang J, Chen Y, Yang J, Li Y, Xue Y. Interleukin-37 suppresses tumor growth through inhibition of angiogenesis in non-small cell lung cancer. J Exp Clin Cancer Res. 2016;35:13.
   PubMed Web of Science ®Google Scholar
• Yang T, Lin Q, Zhao M, Hu Y, Yu Y, Jin J, et al. IL-37 Is a novel proangiogenic factor of developmental and pathological angiogenesis significance. Arterioscler Thromb Vasc Biol. 2015;35:2638–46.
   PubMed Web of Science ®Google Scholar
• van de Veerdonk FL, Stoeckman AK, Wu G, Boeckermann AN, Azam T, Netea MG, et al. IL-38 binds to the IL-36 receptor and has biological effects on immune cells similar to IL-36 receptor antagonist. Proc Natl Acad Sci USA. 2012;109:3001–5.
   PubMed Web of Science ®Google Scholar
• Yuan X, Peng X, Li Y, Li M. Role of IL-38 and its related cytokines in inflammation. Mediators Inflamm. 2015;2015:807976.
   PubMed Web of Science ®Google Scholar
• Takenaka S, Kaieda S, Kawayama T, Matsuoka M, Kaku Y, Kinoshita T, et al. IL-38: a new factor in rheumatoid arthritis. Biochem Biophys Reports. 2015;4:386–91.
   PubMedGoogle Scholar
• Mora J, Schlemmer A, Wittig I, Richter F, Putyrski M, Frank AC, et al. Interleukin-38 is released from apoptotic cells to limit inflammatory macrophage responses. J Mol Cell Biol. 2016;8:426–438.
   PubMed Web of Science ®Google Scholar